AstraZeneca_NNP Annual_JJ Report_NNP and_CC 116_CD Form_NN 20-F_JJ Information_NN 2005_CD NOTES_NNS TO_TO THE_DT FINANCIAL_NNP STATEMENTS_NNS CONTINUED_VBD 25_CD COMMITMENTS_NNS AND_CC CONTINGENT_JJ LIABILITIES_NNS 2005 2004 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD Commitments_NNP Contracts_NNS placed_VBD for_IN future_JJ capital_NN expenditure_NN not_RB provided_VBN for_IN in_IN these_DT accounts_NNS 220 298 421_CD Included_VBN in_IN the_DT above_JJ total_NN are_VBP contracts_NNS related_VBN to_TO certain_JJ product_NN purchase_NN and_CC licence_NN agreements_NNS with_IN deferred_JJ consideration_NN obligations_NNS ,_, the_DT amounts_NNS of_IN which_WDT are_VBP variable_JJ depending_VBG upon_IN particular_JJ milestone_NN achievements_NNS ._.
Sales_NNS of_IN the_DT products_NNS to_TO which_WDT these_DT milestones_NNS relate_VBP could_MD give_VB rise_VB to_TO additional_JJ payments_NNS ,_, contingent_NN upon_IN the_DT sales_NNS levels_NNS achieved_VBN ._.
Guarantees_NNS and_CC contingencies_NNS arising_VBG in_IN the_DT ordinary_JJ course_NN of_IN business_NN ,_, for_IN which_WDT no_DT security_NN has_VBZ been_VBN given_VBN ,_, are_VBP not_RB expected_VBN to_TO result_VB in_IN any_DT material_NN financial_JJ loss_NN ._.
During_IN December_NNP 2005_CD AstraZeneca_NNP entered_VBD into_IN three_CD collaboration_NN agreements_NNS with_IN Protherics_NNPS PLC_NNP ,_, Targacept_NNP ,_, Inc._NNP and_CC AtheroGenics_NNP ,_, Inc._NNP for_IN initial_JJ consideration_NN of_IN $_$ 41m_CD ,_, $_$ 10m_CD and_CC $_$ 50m_CD respectively_RB ._.
The_DT transactions_NNS were_VBD completed_VBN in_IN January_NNP 2006_CD ._.
All_PDT the_DT collaboration_NN agreements_NNS have_VBP deferred_VBN consideration_NN obligations_NNS ,_, dependent_JJ upon_IN particular_JJ milestone_NN events_NNS ._.
AstraZeneca_NNP also_RB entered_VBD into_IN an_DT agreement_NN in_IN December_NNP 2005_CD to_TO acquire_VB the_DT total_JJ share_NN capital_NN of_IN KuDOS_NNP Pharmaceuticals_NNP Limited_NNP for_IN $_$ 210m_CD ._.
The_DT transaction_NN was_VBD completed_VBN in_IN January_NNP 2006_CD ._.
Arrangements_NNS with_IN Merck_NNP Introduction_NNP In_IN 1982_CD ,_, Astra_NNP AB_NNP set_VBD up_RP a_DT joint_JJ venture_NN with_IN Merck_NNP &_CC Co._NNP ._.
Inc._NNP for_IN the_DT purposes_NNS of_IN selling_NN ,_, marketing_NN and_CC distributing_VBG certain_JJ Astra_NNP products_NNS in_IN the_DT US_NNP ._.
In_IN 1998_CD ,_, this_DT joint_JJ venture_NN was_VBD restructured_VBN the_DT Restructuring_NN ._.
Under_IN the_DT agreements_NNS relating_VBG to_TO the_DT Restructuring_NN the_DT Agreements_NNPS ,_, a_DT US_NNP limited_JJ partnership_NN was_VBD formed_VBN ,_, in_IN which_WDT Merck_NNP is_VBZ the_DT limited_JJ partner_NN and_CC AstraZeneca_NNP is_VBZ the_DT general_JJ partner_NN ,_, and_CC AstraZeneca_NNP obtained_VBD control_NN of_IN the_DT joint_JJ ventures_NNS business_NN subject_NN to_TO certain_JJ limited_JJ partner_NN and_CC other_JJ rights_NNS held_VBN by_IN Merck_NNP and_CC its_PRP$ affiliates_NNS ._.
These_DT rights_NNS provide_VBP Merck_NNP with_IN safeguards_NNS over_IN the_DT activities_NNS of_IN the_DT partnership_NN and_CC place_NN limitations_NNS on_IN AstraZenecas_NNP commercial_JJ freedom_NN to_TO operate_VB ._.
The_DT Agreements_NNP provide_VB for_IN :_: Annual_JJ contingent_JJ payments_NNS ._.
A_DT payment_NN to_TO Merck_NNP in_IN the_DT event_NN of_IN a_DT business_NN combination_NN between_IN Astra_NNP and_CC a_DT third_JJ party_NN in_IN order_NN for_IN Merck_NNP to_TO relinquish_VB certain_JJ claims_NNS to_TO that_DT third_JJ partys_NNS products_NNS ._.
Termination_NN arrangements_NNS which_WDT ,_, if_IN and_CC when_WRB triggered_VBN ,_, cause_NN Merck_NNP to_TO relinquish_VB its_PRP$ interests_NNS in_IN AstraZenecas_NNP products_NNS and_CC activities_NNS ._.
These_DT elements_NNS are_VBP discussed_VBN in_IN further_JJ detail_NN below_IN together_RB with_IN a_DT summary_NN of_IN their_PRP$ accounting_NN treatments_NNS ._.
Annual_JJ contingent_JJ payments_NNS AstraZeneca_NNP makes_VBZ ongoing_JJ payments_NNS to_TO Merck_NNP based_VBN on_IN sales_NNS of_IN certain_JJ of_IN its_PRP$ products_NNS in_IN the_DT US_NNP the_DT contingent_JJ payments_NNS on_IN the_DT agreement_NN products_NNS ._.
As_IN a_DT result_NN of_IN the_DT merger_NN of_IN Astra_NNP and_CC Zeneca_NNP in_IN 1999_CD ,_, these_DT contingent_JJ payments_NNS excluding_VBG those_DT in_IN respect_NN of_IN Prilosec_NNP and_CC Nexium_NNP can_MD not_RB be_VB less_JJR than_IN annual_JJ minimum_NN sums_NNS between_IN 2002_CD and_CC 2007_CD ranging_VBG from_IN $_$ 125m_CD to_TO $_$ 225m_CD ._.
AstraZenecas_NNP payments_NNS have_VBP exceeded_VBN the_DT minimum_JJ level_NN in_IN 2002_CD to_TO 2005_CD and_CC ,_, other_JJ than_IN the_DT possible_JJ entry_NN of_IN a_DT generic_JJ competitor_NN to_TO Toprol-XL_NNP ,_, AstraZeneca_NNP has_VBZ no_DT reason_NN to_TO believe_VB that_IN the_DT annual_JJ payments_NNS in_IN the_DT future_NN will_MD fall_VB below_IN the_DT minimum_NN obligations_NNS ._.
Payment_NN in_IN the_DT event_NN of_IN a_DT business_NN combination_NN On_IN the_DT merger_NN of_IN Astra_NNP and_CC Zeneca_NNP ,_, a_DT one-time_JJ Lump_NNP Sum_NNP Payment_NN of_IN $_$ 809m_CD was_VBD triggered_VBN ._.
As_IN a_DT result_NN of_IN this_DT payment_NN ,_, Merck_NNP relinquished_VBD any_DT claims_NNS it_PRP may_MD have_VB had_VBN to_TO Zeneca_NNP products_NNS ._.
Termination_NN arrangements_NNS The_DT Agreements_NNP provided_VBD for_IN arrangements_NNS and_CC payments_NNS under_IN which_WDT ,_, subject_JJ to_TO the_DT exercise_NN of_IN certain_JJ options_NNS ,_, the_DT rights_NNS and_CC interests_NNS in_IN AstraZenecas_NNP activities_NNS and_CC products_NNS held_VBN by_IN Merck_NNP immediately_RB prior_RB to_TO the_DT merger_NN would_MD be_VB terminated_VBN ,_, including_VBG details_NNS of_IN :_: The_DT Advance_NNP Payment_NN The_DT Partial_NNP Retirement_NNP The_NNP First_NNP Option_NN and_CC True-Up_JJ The_DT Loan_NN Note_NN Receivable_NNP The_NNP Second_NNP Option_NN Advance_NNP Payment_NN The_DT merger_NN between_IN Astra_NNP and_CC Zeneca_NNP triggered_VBD the_DT first_JJ step_NN in_IN the_DT termination_NN arrangements_NNS ._.
Merck_NNP relinquished_VBD all_DT rights_NNS ,_, including_VBG contingent_JJ payments_NNS on_IN future_JJ sales_NNS ,_, to_TO potential_JJ Astra_NNP products_NNS with_IN no_DT existing_VBG or_CC pending_VBG US_NNP patents_NNS at_IN the_DT time_NN of_IN the_DT merger_NN ._.
As_IN a_DT result_NN ,_, AstraZeneca_NNP now_RB has_VBZ rights_NNS to_TO such_JJ products_NNS and_CC is_VBZ relieved_VBN of_IN potential_JJ obligations_NNS to_TO Merck_NNP or_CC restrictions_NNS in_IN respect_NN of_IN those_DT products_NNS including_VBG annual_JJ contingent_JJ payments_NNS ,_, affording_VBG AstraZeneca_NNP substantial_JJ freedom_NN to_TO exploit_VB the_DT products_NNS as_IN it_PRP sees_VBZ fit_NN ._.
At_IN the_DT time_NN of_IN the_DT merger_NN ,_, the_DT Advance_NNP Payment_NN was_VBD paid_VBN ._.
It_PRP was_VBD calculated_VBN as_IN the_DT then_RB net_JJ present_JJ value_NN of_IN $_$ 2.8_CD bn_NN discounted_VBN from_IN 2008_CD to_TO the_DT date_NN of_IN merger_NN at_IN a_DT rate_NN of_IN 13_CD %_NN per_IN annum_NN and_CC amounted_VBD to_TO $_$ 967m_CD ._.
It_PRP is_VBZ subject_JJ to_TO a_DT true-up_NN in_IN 2008_CD ,_, as_IN discussed_VBN under_IN First_NNP Option_NN and_CC True-Up_JJ below_IN ._.
Financial_NNP Statements_NNP 117_CD 25_CD COMMITMENTS_NNS AND_CC CONTINGENT_JJ LIABILITIES_NNS CONTINUED_VBD Partial_NNP Retirement_NNP In_IN 2008_CD ,_, there_EX will_MD be_VB a_DT partial_JJ retirement_NN of_IN Mercks_NNP limited_JJ partnership_NN interest_NN by_IN payment_NN to_TO Merck_NNP of_IN an_DT amount_NN calculated_VBN as_IN a_DT multiple_NN of_IN the_DT average_JJ annual_JJ contingent_JJ payments_NNS from_IN 2005_CD to_TO 2007_CD on_IN the_DT relevant_JJ products_NNS ,_, plus_CC $_$ 750m_CD ._.
Upon_IN the_DT Partial_NNP Retirement_NNP ,_, Mercks_NNP rights_NNS in_IN respect_NN of_IN certain_JJ of_IN the_DT agreement_NN products_NNS will_MD end_VB ._.
The_DT products_NNS covered_VBN by_IN the_DT Partial_NNP Retirement_NNP include_VBP Toprol-XL_NNP ,_, Pulmicort_NNP ,_, Rhinocort_NNP and_CC Symbicort_NNP ,_, the_DT last_JJ of_IN which_WDT is_VBZ not_RB yet_RB launched_VBN in_IN the_DT US_NNP and_CC is_VBZ subject_JJ to_TO approval_NN by_IN the_DT FDA_NNP ._.
First_NNP Option_NN and_CC True-Up_JJ In_IN 2008_CD ,_, a_DT calculation_NN will_MD be_VB made_VBN of_IN the_DT Appraised_NNP Value_NNP ,_, being_VBG the_DT net_JJ present_JJ value_NN of_IN the_DT future_JJ contingent_JJ payments_NNS in_IN respect_NN of_IN all_DT agreement_NN products_NNS not_RB covered_VBN by_IN the_DT Partial_NNP Retirement_NNP ,_, other_JJ than_IN Prilosec_NNP and_CC Nexium_NNP ._.
Payment_NN of_IN the_DT Appraised_NNP Value_NNP to_TO Merck_NNP in_IN 2008_CD will_MD take_VB place_NN only_RB if_IN Merck_NNP exercises_VBZ the_DT First_NNP Option_NN ._.
Should_MD Merck_NNP not_RB exercise_VB this_DT option_NN in_IN 2008_CD ,_, AstraZeneca_NNP may_MD exercise_VB it_PRP in_IN 2010_CD for_IN a_DT sum_NN equal_JJ to_TO the_DT 2008_CD Appraised_NNP Value_NNP ._.
Contingent_JJ payments_NNS will_MD continue_VB from_IN 2008_CD to_TO 2010_CD if_IN AstraZeneca_NNP exercises_NNS in_IN 2010_CD ._.
Upon_IN exercise_NN of_IN the_DT First_NNP Option_NN Merck_NNP will_MD relinquish_VB its_PRP$ rights_NNS over_IN the_DT agreement_NN products_NNS not_RB covered_VBN by_IN the_DT Partial_NNP Retirement_NNP ,_, other_JJ than_IN Nexium_NNP and_CC Prilosec_NNP ._.
If_IN neither_DT Merck_NNP nor_CC AstraZeneca_NNP exercises_VBZ the_DT option_NN ,_, the_DT contingent_JJ payment_NN arrangements_NNS in_IN respect_NN of_IN these_DT agreement_NN products_NNS will_MD continue_VB as_RB will_MD AstraZenecas_NNPS other_JJ potential_JJ obligations_NNS and_CC restrictions_NNS in_IN respect_NN of_IN these_DT products_NNS and_CC the_DT Appraised_NNP Value_NNP will_MD not_RB be_VB paid_VBN ._.
Products_NNPS covered_VBN by_IN the_DT First_NNP Option_NN include_VBP Atacand_NNP ,_, Plendil_NNP and_CC certain_JJ compounds_NNS still_RB in_IN development_NN ,_, including_VBG Exanta_NNP ._.
In_IN addition_NN ,_, in_IN 2008_CD there_EX will_MD be_VB a_DT true-up_NN of_IN the_DT Advance_NNP Payment_NN ._.
The_DT true-up_JJ amount_NN will_MD be_VB based_VBN on_IN a_DT multiple_NN of_IN the_DT average_JJ annual_JJ contingent_JJ payments_NNS from_IN 2005_CD to_TO 2007_CD in_IN respect_NN of_IN all_PDT the_DT agreement_NN products_NNS with_IN the_DT exception_NN of_IN Prilosec_NNP and_CC Nexium_NNP subject_JJ to_TO a_DT minimum_NN of_IN $_$ 6.6_CD bn_NN ,_, plus_CC other_JJ defined_VBN amounts_NNS totalling_VBG $_$ 912m_CD ._.
It_PRP is_VBZ then_RB reduced_VBN by_IN the_DT Appraised_NNP Value_NNP whether_IN paid_VBN or_CC not_RB ,_, the_DT Partial_NNP Retirement_NNP and_CC the_DT Advance_NNP Payment_NN at_IN its_PRP$ undiscounted_JJ amount_NN of_IN $_$ 2.8_CD bn_NN to_TO determine_VB the_DT true-up_JJ amount_NN ._.
The_DT true-up_NN will_MD be_VB settled_VBN in_IN 2008_CD irrespective_RB of_IN whether_IN the_DT First_NNP Option_NN is_VBZ exercised_VBN ,_, and_CC this_DT could_MD result_VB in_IN a_DT further_JJ payment_NN by_IN AstraZeneca_NNP to_TO Merck_NNP or_CC a_DT payment_NN by_IN Merck_NNP to_TO AstraZeneca_NNP ._.
Should_MD Merck_NNP exercise_NN the_DT First_NNP Option_NN in_IN 2008_CD ,_, AstraZeneca_NNP will_MD make_VB payments_NNS in_IN respect_NN of_IN the_DT Partial_NNP Retirement_NNP ,_, the_DT First_NNP Option_NN and_CC the_DT trueup_NN totalling_VBG a_DT minimum_NN of_IN $_$ 4.7_CD bn_NN ._.
If_IN AstraZeneca_NNP exercises_VBZ the_DT First_NNP Option_NN in_IN 2010_CD ,_, the_DT combined_VBN effect_NN of_IN the_DT amounts_NNS paid_VBN to_TO Merck_NNP in_IN 2008_CD and_CC 2010_CD will_MD total_VB the_DT same_JJ amount_NN ._.
Loan_NN Note_NN Receivable_NNP Included_VBD in_IN the_DT assets_NNS and_CC liabilities_NNS covered_VBN by_IN the_DT Restructuring_NN is_VBZ a_DT loan_NN note_NN receivable_NN by_IN AstraZeneca_NNP from_IN Merck_NNP with_IN a_DT face_NN value_NN of_IN $_$ 1.4_CD bn_NN ._.
In_IN 2008_CD ,_, at_IN the_DT same_JJ time_NN as_IN the_DT settlement_NN of_IN the_DT Partial_NNP Retirement_NNP and_CC the_DT true-up_NN ,_, Merck_NNP will_MD settle_VB the_DT loan_NN note_NN receivable_NN by_IN paying_VBG AstraZeneca_NNP $_$ 1.4_CD bn_NN ._.
Second_JJ Option_NN A_DT Second_JJ Option_NN exists_VBZ whereby_WRB AstraZeneca_NNP has_VBZ the_DT option_NN to_TO re-purchase_VB Mercks_NNP interests_NNS in_IN Prilosec_NNP and_CC Nexium_NNP in_IN the_DT US_NNP ._.
This_DT option_NN is_VBZ exercisable_JJ by_IN AstraZeneca_NNP two_CD years_NNS after_IN the_DT exercise_NN of_IN the_DT First_NNP Option_NN ,_, whether_IN the_DT First_NNP Option_NN is_VBZ exercised_VBN in_IN either_DT 2008_CD or_CC 2010_CD ._.
Exercise_NN of_IN the_DT Second_JJ Option_NN by_IN AstraZeneca_NNP at_IN a_DT later_JJ date_NN is_VBZ also_RB provided_VBN for_IN in_IN 2017_CD or_CC if_IN combined_VBN annual_JJ sales_NNS of_IN the_DT two_CD products_NNS fall_VBP below_IN a_DT minimum_JJ amount_NN provided_VBN ,_, in_IN each_DT case_NN ,_, that_IN the_DT First_NNP Option_NN has_VBZ been_VBN exercised_VBN ._.
The_DT exercise_NN price_NN for_IN the_DT Second_JJ Option_NN is_VBZ the_DT net_JJ present_JJ value_NN of_IN the_DT future_JJ annual_JJ contingent_JJ payments_NNS on_IN Prilosec_NNP and_CC Nexium_NNP as_IN determined_VBN at_IN the_DT time_NN of_IN exercise_NN ._.
If_IN the_DT Second_JJ Option_NN is_VBZ exercised_VBN ,_, Merck_NNP will_MD then_RB have_VB relinquished_VBN all_DT its_PRP$ interests_NNS in_IN the_DT partnership_NN and_CC the_DT agreement_NN products_NNS including_VBG rights_NNS to_TO contingent_JJ payments_NNS ._.
General_NNP The_NNP precise_JJ amount_NN and_CC timing_NN of_IN settlements_NNS with_IN Merck_NNP under_IN the_DT Partial_NNP Retirement_NNP ,_, the_DT First_NNP Option_NN and_CC the_DT true-up_NN can_MD not_RB be_VB determined_VBN at_IN this_DT time_NN ._.
Various_JJ components_NNS of_IN the_DT calculations_NNS are_VBP based_VBN ,_, in_IN part_NN ,_, on_IN net_JJ sales_NNS between_IN 2005_CD and_CC 2007_CD and_CC on_IN forecasted_JJ performance_NN beyond_IN 2007_CD ,_, and_CC payment_NN of_IN the_DT First_NNP Option_NN is_VBZ contingent_JJ upon_IN Merck_NNP or_CC AstraZeneca_NNP exercising_VBG the_DT First_NNP Option_NN ._.
Similarly_RB ,_, the_DT timing_NN and_CC amount_NN of_IN the_DT Second_JJ Option_NN can_MD not_RB be_VB determined_VBN at_IN this_DT time_NN ._.
With_IN the_DT exception_NN of_IN the_DT interests_NNS in_IN Nexium_NNP and_CC Prilosec_NNP ,_, the_DT total_NN of_IN the_DT payments_NNS yet_RB to_TO be_VB made_VBN under_IN the_DT termination_NN arrangements_NNS is_VBZ based_VBN ,_, in_IN part_NN ,_, on_IN the_DT contingent_JJ payments_NNS made_VBN in_IN 2005_CD to_TO 2007_CD subject_JJ to_TO the_DT minimum_NN amount_NN and_CC is_VBZ likely_JJ to_TO be_VB substantially_RB driven_VBN by_IN the_DT sales_NNS of_IN Toprol-XL_NNP ,_, Pulmicort_NNP ,_, Rhinocort_NNP and_CC Atacand_NNP ._.
However_RB ,_, AstraZeneca_NNP anticipates_VBZ that_IN the_DT benefits_NNS that_WDT accrue_VBP under_IN all_PDT the_DT termination_NN arrangements_NNS arise_VB :_: Currently_NNP ,_, from_IN the_DT substantial_JJ freedom_NN over_IN products_NNS acquired_VBN or_CC discovered_VBN post-merger_NN ._.
On_IN occurrence_NN of_IN each_DT stage_NN of_IN such_JJ arrangements_NNS ,_, from_IN enhanced_JJ contributions_NNS from_IN ,_, and_CC substantial_JJ freedom_NN over_IN ,_, those_DT products_NNS that_WDT have_VBP already_RB been_VBN launched_VBN for_IN example_NN ,_, Rhinocort_NNP and_CC Atacand_NNP ,_, those_DT that_WDT are_VBP due_JJ to_TO be_VB launched_VBN in_IN the_DT US_NNP in_IN particular_JJ ,_, Symbicort_NNP ,_, subject_JJ to_TO approval_NN by_IN the_DT FDA_NNP and_CC those_DT that_WDT are_VBP in_IN development_NN ._.
Benefits_NNS include_VBP relief_NN from_IN contingent_JJ payments_NNS ,_, anticipated_VBN cost_NN savings_NNS from_IN cessation_NN of_IN manufacturing_VBG arrangements_NNS and_CC other_JJ cost_NN efficiencies_NNS together_RB with_IN the_DT strategic_JJ advantages_NNS of_IN increased_VBN freedom_NN to_TO operate_VB ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC 118_CD Form_NN 20-F_JJ Information_NN 2005_CD NOTES_NNS TO_TO THE_DT FINANCIAL_NNP STATEMENTS_NNS CONTINUED_VBD 25_CD COMMITMENTS_NNS AND_CC CONTINGENT_JJ LIABILITIES_NNS CONTINUED_VBD Accounting_NNP treatments_NNS Annual_JJ contingent_NN payments_NNS :_: The_DT annual_JJ contingent_JJ payments_NNS on_IN agreement_NN products_NNS are_VBP expensed_VBN as_IN incurred_VBN ._.
Payment_NN in_IN the_DT event_NN of_IN a_DT business_NN combination_NN :_: The_DT Lump_NNP Sum_NNP Payment_NN was_VBD expensed_VBN at_IN the_DT point_NN of_IN merger_NN since_IN it_PRP caused_VBD no_DT incremental_JJ benefits_NNS over_IN the_DT prior_JJ years_NNS aggregate_JJ Astra_NNP and_CC Zeneca_NNP performance_NN to_TO accrue_VB to_TO the_DT merged_JJ AstraZeneca_NNP entity_NN ._.
Termination_NN arrangements_NNS :_: AstraZeneca_NNP considers_VBZ that_IN the_DT termination_NN arrangements_NNS described_VBN above_IN represent_VBP the_DT acquisition_NN ,_, in_IN stages_NNS ,_, of_IN Mercks_NNP interests_NNS in_IN the_DT partnership_NN and_CC agreement_NN products_NNS including_VBG Mercks_NNP rights_NNS to_TO contingent_JJ payments_NNS and_CC depend_VB ,_, in_IN part_NN ,_, on_IN the_DT exercise_NN of_IN the_DT First_NNP and_CC Second_NNP Options_NNPS ._.
The_DT effects_NNS will_MD only_RB be_VB reflected_VBN in_IN the_DT Financial_NNP Statements_NNP as_IN these_DT stages_NNS are_VBP reached_VBN ._.
If_IN and_CC when_WRB all_DT such_JJ payments_NNS are_VBP made_VBN ,_, AstraZeneca_NNP will_MD have_VB unencumbered_JJ discretion_NN in_IN its_PRP$ operations_NNS in_IN the_DT US_NNP market_NN ._.
The_DT Advance_NNP Payment_NN has_VBZ been_VBN accounted_VBN for_IN as_IN an_DT intangible_JJ asset_NN and_CC is_VBZ being_VBG amortised_VBN over_IN 20_CD years_NNS ._.
This_DT approach_NN reflects_VBZ the_DT fact_NN that_IN ,_, under_IN the_DT Agreements_NNP ,_, AstraZeneca_NNP has_VBZ acquired_VBN rights_NNS relieving_VBG it_PRP of_IN potential_JJ obligations_NNS or_CC restrictions_NNS in_IN respect_NN of_IN Astra_NNP products_NNS with_IN no_DT existing_VBG or_CC pending_VBG patents_NNS at_IN the_DT time_NN of_IN merger_NN ._.
Although_IN these_DT rights_NNS apply_VBP in_IN perpetuity_NN ,_, the_DT period_NN of_IN amortisation_NN of_IN 20_CD years_NNS has_VBZ been_VBN chosen_VBN to_TO reflect_VB the_DT typical_JJ timescale_NN of_IN development_NN and_CC marketing_NN of_IN a_DT product_NN ._.
The_DT payments_NNS under_IN the_DT Partial_NNP Retirement_NNP ,_, the_DT First_NNP Option_NN and_CC true-up_NN and_CC the_DT Second_JJ Option_NN will_MD be_VB accounted_VBN for_IN under_IN the_DT extant_JJ guidance_NN when_WRB they_PRP are_VBP paid_VBN ,_, with_IN allocations_NNS to_TO intangibles_NNS and_CC goodwill_NN ,_, as_IN appropriate_JJ ._.
If_IN Merck_NNP exercises_VBZ the_DT First_NNP Option_NN in_IN 2008_CD ,_, the_DT net_JJ minimum_NN payment_NN to_TO be_VB made_VBN to_TO Merck_NNP ,_, being_VBG the_DT combined_VBN payments_NNS of_IN $_$ 4.7_CD bn_NN less_JJR the_DT repayment_NN of_IN the_DT loan_NN note_NN of_IN $_$ 1.4_CD bn_NN ,_, would_MD be_VB $_$ 3.3_CD bn_NN ._.
In_IN accounting_NN for_IN the_DT Restructuring_NN in_IN 1998_CD ,_, the_DT loan_NN note_NN was_VBD included_VBN in_IN the_DT determination_NN of_IN the_DT fair_JJ values_NNS of_IN the_DT assets_NNS and_CC liabilities_NNS to_TO be_VB acquired_VBN ._.
At_IN that_DT time_NN ,_, the_DT loan_NN note_NN was_VBD ascribed_VBN a_DT fair_JJ value_NN of_IN zero_CD on_IN acquisition_NN and_CC on_IN the_DT balance_NN sheet_NN because_IN it_PRP was_VBD estimated_VBN that_IN the_DT net_JJ minimum_NN payment_NN of_IN $_$ 3.3_CD bn_NN equated_VBN to_TO the_DT fair_JJ value_NN of_IN the_DT rights_NNS to_TO be_VB acquired_VBN under_IN the_DT Partial_NNP Retirement_NNP ,_, true-up_NN and_CC First_JJ Option_NN ._.
Ongoing_JJ monitoring_NN of_IN the_DT projected_VBN payments_NNS to_TO Merck_NNP and_CC the_DT value_NN to_TO AstraZeneca_NNP of_IN the_DT related_JJ rights_NNS takes_VBZ full_JJ account_NN of_IN changing_VBG business_NN circumstances_NNS and_CC the_DT range_NN of_IN possible_JJ outcomes_NNS to_TO ensure_VB that_IN the_DT payments_NNS to_TO be_VB made_VBN to_TO Merck_NNP are_VBP covered_VBN by_IN the_DT economic_JJ benefits_NNS expected_VBN to_TO be_VB realized_VBN ._.
Should_MD the_DT monitoring_NN reveal_VBP that_IN these_DT payments_NNS exceed_VBP the_DT economic_JJ benefits_NNS expected_VBN to_TO be_VB realized_VBN ,_, a_DT provision_NN for_IN an_DT onerous_JJ contract_NN would_MD be_VB recognized_VBN ._.
Environmental_JJ costs_NNS and_CC liabilities_NNS The_DT Groups_NNS expenditure_NN on_IN environmental_JJ protection_NN ,_, including_VBG both_DT capital_NN and_CC revenue_NN items_NNS ,_, relates_VBZ to_TO costs_NNS which_WDT are_VBP necessary_JJ for_IN implementing_VBG internal_JJ systems_NNS and_CC programs_NNS and_CC meeting_VBG legal_JJ and_CC regulatory_JJ requirements_NNS for_IN processes_NNS and_CC products_NNS ._.
They_PRP are_VBP an_DT integral_JJ part_NN of_IN normal_JJ ongoing_JJ expenditure_NN for_IN carrying_VBG out_RP the_DT Groups_NNS research_NN ,_, manufacturing_NN and_CC commercial_JJ operations_NNS and_CC are_VBP not_RB separated_VBN from_IN overall_JJ operating_NN and_CC development_NN costs_NNS ._.
There_EX are_VBP no_DT known_VBN changes_NNS in_IN legal_JJ ,_, regulatory_JJ or_CC other_JJ requirements_NNS resulting_VBG in_IN material_NN changes_NNS to_TO the_DT levels_NNS of_IN expenditure_NN for_IN 2003_CD ,_, 2004_CD or_CC 2005_CD ._.
In_IN addition_NN to_TO expenditure_NN for_IN meeting_NN current_JJ and_CC foreseen_VBN environmental_JJ protection_NN requirements_NNS ,_, the_DT Group_NNP incurs_VBZ costs_NNS in_IN investigating_VBG and_CC cleaning_VBG up_RP land_NN and_CC groundwater_NN contamination_NN ._.
In_IN particular_JJ ,_, AstraZeneca_NNP and_CC or_CC its_PRP$ affiliates_NNS have_VBP environmental_JJ liabilities_NNS at_IN some_DT currently_RB or_CC formerly_RB owned_VBN ,_, leased_VBN and_CC third_JJ party_NN sites_NNS ._.
In_IN the_DT US_NNP ,_, the_DT AstraZeneca_NNP affiliate_NN ,_, Zeneca_NNP Inc._NNP and_CC or_CC its_PRP$ indemnitees_NNS ,_, have_VBP been_VBN named_VBN as_IN potentially_RB responsible_JJ parties_NNS PRPs_NNS or_CC defendants_NNS at_IN approximately_RB 14_CD sites_NNS where_WRB Zeneca_NNP Inc._NNP is_VBZ likely_JJ to_TO incur_VB future_JJ investigation_NN ,_, remediation_NN or_CC operation_NN and_CC maintenance_NN costs_NNS under_IN federal_JJ or_CC state_NN ,_, statutory_JJ or_CC common_JJ law_NN environmental_JJ liability_NN allocations_NNS schemes_NNS ._.
Similarly_RB ,_, the_DT AstraZeneca_NNP affiliate_NN ,_, Stauffer_NNP Management_NNP Company_NNP LLC_NNP SMC_NNP ,_, which_WDT was_VBD established_VBN in_IN 1987_CD to_TO own_VB and_CC manage_VB certain_JJ assets_NNS of_IN Stauffer_NNP Chemical_NNP Company_NNP acquired_VBD that_DT year_NN ,_, and_CC or_CC its_PRP$ indemnitees_NNS ,_, have_VBP been_VBN named_VBN as_IN PRPs_NNS or_CC defendants_NNS at_IN approximately_RB 32_CD sites_NNS where_WRB SMC_NNP is_VBZ likely_JJ to_TO incur_VB future_JJ investigation_NN ,_, remediation_NN or_CC operation_NN and_CC maintenance_NN costs_NNS under_IN federal_JJ or_CC state_NN ,_, statutory_JJ or_CC common_JJ law_NN environmental_JJ liability_NN allocations_NNS schemes_NNS ._.
In_IN Europe_NNP and_CC other_JJ parts_NNS of_IN the_DT world_NN outside_IN the_DT US_NNP ,_, AstraZeneca_NNP is_VBZ likely_JJ to_TO incur_VB costs_NNS at_IN three_CD currently_RB owned_VBN sites_NNS and_CC has_VBZ given_VBN indemnities_NNS to_TO third_JJ parties_NNS in_IN respect_NN of_IN approximately_RB 45_CD other_JJ sites_NNS ._.
These_DT environmental_JJ liabilities_NNS arise_VBP almost_RB entirely_RB from_IN legacy_NN operations_NNS that_WDT are_VBP not_RB part_NN of_IN our_PRP$ current_JJ pharmaceuticals_NNS business_NN and_CC ,_, at_IN most_JJS of_IN these_DT sites_NNS ,_, remediation_NN ,_, where_WRB required_VBN ,_, is_VBZ either_RB completed_VBN or_CC nearing_VBG completion_NN ._.
In_IN the_DT aggregate_NN ,_, however_RB ,_, expenditure_NN on_IN clean_JJ up_RB and_CC monitoring_NN is_VBZ likely_JJ to_TO be_VB required_VBN ._.
AstraZeneca_NNP has_VBZ made_VBN provisions_NNS for_IN the_DT estimated_VBN costs_NNS of_IN future_JJ environmental_JJ investigation_NN ,_, remediation_NN and_CC operation_NN and_CC maintenance_NN activity_NN beyond_IN normal_JJ ongoing_JJ expenditure_NN for_IN maintaining_VBG the_DT Groups_NNS R&D_NNP and_CC manufacturing_VBG capacity_NN and_CC product_NN ranges_NNS where_WRB a_DT present_JJ obligation_NN exists_VBZ ,_, it_PRP is_VBZ probable_JJ that_IN such_JJ costs_NNS will_MD be_VB incurred_VBN ,_, and_CC they_PRP can_MD be_VB estimated_VBN reliably_RB ._.
With_IN respect_NN to_TO such_JJ estimated_VBN ,_, future_JJ costs_NNS ,_, there_EX were_VBD provisions_NNS at_IN 31_CD December_NNP 2005_CD in_IN the_DT aggregate_NN of_IN approximately_RB $_$ 80m_CD ,_, of_IN which_WDT approximately_RB $_$ 68m_CD relates_VBZ to_TO the_DT US_NNP ._.
These_DT provisions_NNS do_VBP not_RB include_VB possible_JJ additional_JJ costs_NNS that_WDT are_VBP not_RB currently_RB probable_JJ ,_, nor_CC do_VB these_DT provisions_NNS include_VBP costs_NNS that_IN ,_, by_IN agreement_NN ,_, will_MD be_VB borne_VBN by_IN viable_JJ third_JJ party_NN indemnitors_NNS ._.
In_IN addition_NN ,_, these_DT provisions_NNS :_: 1_CD include_VBP ,_, where_WRB appropriate_JJ ,_, unasserted_JJ claims_NNS where_WRB future_JJ costs_NNS are_VBP nonetheless_RB probable_JJ at_IN owned_VBN sites_NNS ,_, for_IN example_NN :_: 2_CD are_VBP based_VBN ,_, where_WRB applicable_JJ ,_, on_IN liability_NN allocation_NN or_CC cost_NN sharing_NN agreements_NNS that_IN we_PRP believe_VBP are_VBP enforceable_JJ against_IN viable_JJ third_JJ parties_NNS :_: 3_CD reflect_VBP expected_VBN insurance_NN recoveries_NNS where_WRB an_DT insurer_NN has_VBZ agreed_VBN to_TO provide_VB an_DT indemnity_NN :_: and_CC 4_CD typically_RB cover_VBP a_DT time_NN period_NN of_IN five_CD years_NNS with_IN the_DT exception_NN of_IN operation_NN and_CC maintenance_NN activities_NNS ,_, which_WDT can_MD last_VB for_IN decades_NNS ._.
AstraZeneca_NNP is_VBZ not_RB presently_RB aware_JJ of_IN any_DT circumstances_NNS or_CC uncertainties_NNS regarding_VBG the_DT viability_NN of_IN liable_JJ third_JJ parties_NNS ,_, indemnitors_NNS or_CC insurers_NNS that_WDT would_MD cause_VB these_DT provisions_NNS to_TO be_VB altered_VBN ._.
Financial_NNP Statements_NNP 119_CD 25_CD COMMITMENTS_NNS AND_CC CONTINGENT_JJ LIABILITIES_NNS CONTINUED_VBD It_PRP is_VBZ possible_JJ that_IN the_DT Company_NN ,_, or_CC its_PRP$ affiliates_NNS ,_, could_MD incur_VB future_JJ environmental_JJ costs_NNS beyond_IN the_DT extent_NN of_IN our_PRP$ current_JJ provisions_NNS ._.
The_DT extent_NN of_IN such_JJ possible_JJ ,_, additional_JJ costs_NNS is_VBZ inherently_RB difficult_JJ to_TO estimate_VB due_JJ to_TO a_DT number_NN of_IN factors_NNS ,_, including_VBG ,_, but_CC not_RB limited_VBN to_TO :_: 1_CD the_DT nature_NN and_CC extent_NN of_IN claims_NNS that_WDT may_MD be_VB asserted_VBN in_IN the_DT future_NN :_: 2_CD whether_IN the_DT Company_NN or_CC any_DT of_IN its_PRP$ affiliates_NNS has_VBZ or_CC will_MD have_VB any_DT legal_JJ obligation_NN with_IN respect_NN to_TO asserted_VBD or_CC unasserted_JJ claims_NNS :_: 3_CD the_DT type_NN of_IN remedial_JJ action_NN ,_, if_IN any_DT ,_, that_WDT may_MD be_VB selected_VBN at_IN sites_NNS where_WRB the_DT remedy_NN is_VBZ presently_RB not_RB known_VBN :_: 4_LS the_DT potential_NN for_IN recoveries_NNS from_IN or_CC allocation_NN of_IN liability_NN to_TO third_JJ parties_NNS :_: and_CC 5_CD the_DT length_NN of_IN time_NN that_IN the_DT environmental_JJ investigation_NN ,_, remediation_NN and_CC liability_NN allocation_NN process_NN can_MD take_VB ._.
Notwithstanding_IN and_CC subject_JJ to_TO the_DT foregoing_NN ,_, it_PRP is_VBZ estimated_VBN that_IN potential_JJ additional_JJ loss_NN for_IN future_JJ environmental_JJ investigation_NN ,_, remediation_NN and_CC remedial_JJ operation_NN and_CC maintenance_NN activity_NN above_IN and_CC beyond_IN our_PRP$ provisions_NNS could_MD be_VB ,_, in_IN the_DT aggregate_NN ,_, in_IN the_DT order_NN of_IN $_$ 20m_CD to_TO $_$ 40m_CD ._.
Legal_JJ proceedings_NNS AstraZeneca_NNP is_VBZ involved_VBN in_IN various_JJ legal_JJ proceedings_NNS considered_VBN typical_JJ to_TO its_PRP$ businesses_NNS ,_, including_VBG litigation_NN relating_VBG to_TO employment_NN ,_, product_NN liability_NN ,_, commercial_JJ disputes_NNS ,_, infringement_NN of_IN intellectual_JJ property_NN rights_NNS ,_, the_DT validity_NN of_IN certain_JJ patents_NNS ,_, and_CC securities_NNS law_NN ._.
The_DT more_JJR significant_JJ matters_NNS are_VBP discussed_VBN below_IN ._.
Crestor_NNP rosuvastatin_NN AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP and_CC or_CC AstraZeneca_NNP LP_NNP in_IN the_DT US_NNP were_VBD served_VBN with_IN two_CD individual_JJ lawsuits_NNS in_IN 2004_CD involving_VBG alleged_JJ injury_NN in_IN association_NN with_IN the_DT use_NN of_IN Crestor_NNP ._.
One_CD of_IN these_DT lawsuits_NNS has_VBZ now_RB been_VBN dismissed_VBN ._.
In_IN addition_NN ,_, a_DT motion_NN for_IN authorisation_NN to_TO institute_VB a_DT class_NN action_NN and_CC to_TO be_VB a_DT representative_NN was_VBD filed_VBN in_IN Quebec_NNP ,_, Canada_NNP against_IN AstraZeneca_NNP PLC_NNP and_CC AstraZeneca_NNP Canada_NNP Inc._NNP ._.
The_DT petitioner_NN claims_VBZ alleged_JJ injury_NN as_IN a_DT result_NN of_IN the_DT use_NN of_IN Crestor_NNP ._.
During_IN 2005_CD ,_, AstraZeneca_NNP was_VBD served_VBN with_IN five_CD other_JJ similar_JJ complaints_NNS in_IN the_DT US_NNP ,_, two_CD of_IN which_WDT were_VBD recently_RB dismissed_VBN ._.
AstraZeneca_NNP is_VBZ vigorously_RB defending_VBG all_PDT the_DT remaining_VBG actions_NNS ._.
Diprivan_NNP propofol_NN In_IN August_NNP 2002_CD ,_, AstraZeneca_NNP LP_NNP received_VBD a_DT letter_NN from_IN ESI_NNP Lederle_NNP ,_, a_DT division_NN of_IN Wyeth_NNP ,_, informing_VBG AstraZeneca_NNP of_IN Wyeths_NNP intention_NN to_TO market_VB a_DT generic_JJ version_NN of_IN Diprivan_NNP prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patents_NNS covering_VBG the_DT current_JJ formulation_NN ._.
AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN Wyeth_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP ._.
Through_IN a_DT series_NN of_IN transactions_NNS ,_, the_DT holder_NN of_IN the_DT relevant_JJ Abbreviated_NNP New_NNP Drug_NNP Application_NNP and_CC now_RB defendant_NN in_IN AstraZenecas_NNP suit_NN is_VBZ Mayne_NNP Pharma_NNP USA_NNP Inc._NNP formerly_RB called_VBD Faulding_NNP Pharmaceutical_NNP Co._NNP ._.
Mayne_NNP responded_VBD to_TO AstraZenecas_NNP complaint_NN and_CC filed_VBD counterclaims_NNS alleging_VBG non-infringement_JJ ,_, invalidity_NN and_CC unenforceability_NN ._.
The_DT trial_NN ,_, post-trial_JJ briefing_NN and_CC closing_NN arguments_NNS took_VBD place_NN in_IN early_JJ 2005_CD ._.
In_IN November_NNP 2005_CD ,_, the_DT court_NN issued_VBD its_PRP$ decision_NN finding_VBG the_DT AstraZeneca_NNP patents_NNS to_TO be_VB valid_JJ and_CC enforceable_JJ and_CC infringed_VBN by_IN Maynes_NNP propofol_NN product_NN ._.
The_DT court_NN has_VBZ issued_VBN an_DT injunction_NN preventing_VBG the_DT manufacture_NN ,_, use_NN ,_, sale_NN and_CC offering_NN for_IN sale_NN in_IN the_DT US_NNP of_IN Maynes_NNP propofol_NN product_NN ._.
Mayne_NNP has_VBZ filed_VBN an_DT appeal_NN of_IN the_DT courts_NNS findings_NNS to_TO the_DT Federal_NNP Circuit_NNP Court_NNP of_IN Appeals_NNPS ._.
In_IN September_NNP 2005_CD ,_, AstraZeneca_NNP received_VBD notification_NN from_IN Amphastar_NNP Pharmaceuticals_NNP Inc._NNP under_IN section_NN 505_CD b_NN 2_CD of_IN the_DT US_NNP Food_NNP ,_, Drug_NNP and_CC Cosmetic_NNP Act_NNP that_IN ,_, after_IN approval_NN by_IN the_DT FDA_NNP ,_, it_PRP intends_VBZ to_TO manufacture_VB and_CC sell_VB propofol_NN in_IN the_DT US_NNP prior_RB to_TO the_DT expiration_NN of_IN certain_JJ of_IN AstraZenecas_NNP propofol-related_JJ patents_NNS ._.
Amphastar_NNP contends_VBZ that_IN these_DT patents_NNS would_MD not_RB be_VB infringed_VBN by_IN such_JJ manufacture_NN and_CC sale_NN ._.
AstraZeneca_NNP did_VBD not_RB file_VB a_DT patent_NN infringement_NN complaint_NN against_IN Amphastar_NNP ._.
Exanta_NNP ximelagatran_NN Four_CD putative_NN and_CC essentially_RB similar_JJ securities_NNS class_NN actions_NNS were_VBD filed_VBN in_IN the_DT US_NNP against_IN AstraZeneca_NNP PLC_NNP ,_, Hkan_NNP Mogren_NNP ,_, Sir_NNP Tom_NNP McKillop_NNP ,_, Jonathan_NNP Symonds_NNPS and_CC Percy_NNP Barnevik_NNP between_IN January_NNP and_CC March_NNP 2005_CD ._.
These_DT actions_NNS allege_VBP that_IN the_DT defendants_NNS made_VBD materially_RB false_JJ and_CC misleading_JJ statements_NNS regarding_VBG Exanta_NNP clinical_JJ trials_NNS and_CC the_DT status_NN of_IN the_DT Exanta_NNP New_NNP Drug_NNP Application_NNP in_IN the_DT US_NNP ._.
The_DT cases_NNS purport_VBP to_TO assert_VB claims_NNS on_IN behalf_NN of_IN purchasers_NNS of_IN AstraZeneca_NNP publicly_RB traded_VBD securities_NNS during_IN the_DT period_NN 2_CD April_NNP 2003_CD to_TO 11_CD October_NNP 2004_CD under_IN sections_NNS 10_CD b_NN and_CC 20_CD a_DT of_IN the_DT Securities_NNP Exchange_NNP Act_NNP of_IN 1934_CD and_CC SEC_NNP Rule_NNP 10b-5_JJ ._.
The_DT cases_NNS were_VBD all_DT filed_VBN in_IN federal_JJ district_NN courts_NNS one_CD in_IN the_DT District_NNP of_IN Massachusetts_NNP ,_, one_CD in_IN the_DT District_NNP of_IN Delaware_NNP and_CC two_CD in_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP ._.
The_DT Delaware_NNP case_NN was_VBD dismissed_VBN voluntarily_RB and_CC the_DT Massachusetts_NNP case_NN has_VBZ been_VBN transferred_VBN to_TO the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP by_IN way_NN of_IN stipulation_NN ._.
The_DT remaining_VBG cases_NNS are_VBP likely_JJ to_TO be_VB consolidated_VBN in_IN a_DT single_JJ action_NN in_IN New_NNP York_NNP ._.
The_DT defendants_NNS deny_VBP the_DT allegations_NNS made_VBN in_IN the_DT lawsuits_NNS and_CC will_MD vigorously_RB defend_VB the_DT actions_NNS ._.
Iressa_NNP gefitinib_NN During_IN 2004_CD and_CC 2005_CD ,_, five_CD claims_NNS have_VBP been_VBN filed_VBN against_IN AstraZeneca_NNP KK_NNP in_IN Japan_NNP ,_, in_IN the_DT Osaka_NNP and_CC Tokyo_NNP District_NNP Courts_NNPS ._.
In_IN four_CD of_IN the_DT claims_NNS ,_, it_PRP is_VBZ alleged_VBN that_IN Iressa_NNP caused_VBD a_DT fatal_JJ incidence_NN of_IN interstitial_JJ lung_NN disease_NN ILD_NNP in_IN a_DT Japanese_JJ patient_NN ._.
In_IN the_DT fifth_JJ claim_NN ,_, which_WDT did_VBD not_RB involve_VB a_DT fatality_NN ,_, it_PRP is_VBZ alleged_VBN that_IN Iressa_NNP caused_VBD an_DT incidence_NN of_IN ILD_NNP ._.
AstraZeneca_NNP KK_NNP ,_, following_VBG consultation_NN with_IN external_JJ legal_JJ advisers_NNS ,_, believes_VBZ the_DT claims_NNS are_VBP without_IN merit_NN and_CC is_VBZ defending_VBG all_DT of_IN the_DT cases_NNS ._.
ILD_NNP is_VBZ a_DT known_JJ complication_NN of_IN lung_NN disease_NN ,_, including_VBG advanced_JJ lung_NN cancer_NN ,_, regardless_RB of_IN treatment_NN ._.
Losec_NNP Prilosec_NNP omeprazole_NN In_IN 2001_CD ,_, AstraZeneca_NNP filed_VBD suit_NN in_IN the_DT US_NNP against_IN Andrx_NNP Pharmaceuticals_NNP ,_, Inc._NNP for_IN infringement_NN of_IN a_DT patent_NN directed_VBD to_TO a_DT process_NN for_IN making_VBG an_DT omeprazole_NN formulation_NN the_DT 281_CD patent_NN ._.
Andrx_NNP filed_VBD counterclaims_NNS of_IN non-infringement_NN ,_, invalidity_NN and_CC unenforceability_NN for_IN inequitable_JJ conduct_NN during_IN prosecution_NN of_IN the_DT 281_CD patent_NN ._.
Andrx_NNP also_RB asserted_VBD that_IN in_IN addition_NN to_TO the_DT 281_CD patent_NN ,_, two_CD other_JJ formulation_NN patents_NNS ,_, the_DT 505_CD and_CC 230_CD patents_NNS ,_, were_VBD unenforceable_JJ for_IN alleged_JJ litigation_NN misconduct_NN by_IN AstraZeneca_NNP ._.
Both_DT parties_NNS sought_VBD attorneys_NNS fees_NNS ._.
In_IN May_NNP 2004_CD ,_, the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP ruled_VBD that_IN the_DT 281_CD patent_NN was_VBD infringed_VBN ,_, but_CC also_RB ruled_VBD that_IN the_DT 281_CD patent_NN was_VBD invalid_JJ ._.
The_DT court_NN dismissed_VBD Andrxs_NNP litigation_NN misconduct_NN and_CC other_JJ counterclaims_NNS and_CC affirmative_JJ defences_NNS ,_, leaving_VBG intact_JJ the_DT courts_NNS October_NNP 2002_CD decision_NN finding_VBG the_DT 230_CD and_CC 505_CD patents_NNS not_RB invalid_JJ and_CC infringed_VBN by_IN Andrx_NNP ._.
The_DT October_NNP 2002_CD decision_NN was_VBD affirmed_VBN in_IN all_DT respects_NNS on_IN appeal_NN in_IN December_NNP 2003_CD ._.
The_DT court_NN entered_VBD final_JJ judgement_NN regarding_VBG the_DT 281_CD patent_NN in_IN July_NNP 2004_CD ,_, after_IN determining_VBG to_TO stay_VB the_DT attorneys_NNS fees_NNS claims_NNS pending_VBG any_DT appeals_NNS ._.
Andrx_NNP has_VBZ appealed_VBN the_DT judgement_NN and_CC AstraZeneca_NNP has_VBZ cross-appealed_VBN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC 120_CD Form_NN 20-F_JJ Information_NN 2005_CD NOTES_NNS TO_TO THE_DT FINANCIAL_NNP STATEMENTS_NNS CONTINUED_VBD 25_CD COMMITMENTS_NNS AND_CC CONTINGENT_JJ LIABILITIES_NNS CONTINUED_VBD During_IN 2000_CD and_CC 2001_CD ,_, AstraZeneca_NNP had_VBD filed_VBN suits_NNS against_IN Lek_NNP Pharmaceutical_NNP and_CC Chemical_NNP Company_NNP d._NNP d._NN and_CC Lek_NNP Services_NNPS USA_NNP ,_, Inc._NNP ._.
Impax_NNP Laboratories_NNPS Inc._NNP ._.
Eon_NNP Labs_NNPS Manufacturing_NNP Inc._NNP ._.
Mylan_NNP Pharmaceuticals_NNP Inc._NNP ._.
Apotex_NNP Corp_NNP ,_, Apotex_NNP ,_, Inc._NNP and_CC Torpharm_NNP ,_, Inc._NNP and_CC Zenith_NNP Goldline_NNP Pharmaceuticals_NNP ,_, Inc._NNP now_RB known_VBN as_IN IVAX_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
These_DT suits_NNS followed_VBD the_DT filing_NN of_IN Abbreviated_NNP New_NNP Drug_NNP Applica_NNP tions_NNS by_IN these_DT companies_NNS with_IN the_DT FDA_NNP concerning_VBG the_DT companies_NNS intention_NN to_TO market_NN generic_JJ omeprazole_NN products_NNS in_IN the_DT US_NNP ._.
The_DT basis_NN for_IN the_DT proceedings_NNS is_VBZ that_IN the_DT actions_NNS of_IN all_PDT the_DT companies_NNS infringe_VBP the_DT 505_CD and_CC 230_CD formulation_NN patents_NNS relating_VBG to_TO omeprazole_NN ._.
The_DT cases_NNS are_VBP proceeding_VBG under_IN the_DT US_NNP Hatch-Waxman_NNP legislation_NN ._.
The_DT case_NN against_IN IVAX_NNP was_VBD dismissed_VBN without_IN prejudice_NN shortly_RB after_IN it_PRP was_VBD filed_VBN ,_, after_IN IVAXwithdrew_NNP its_PRP$ application_NN to_TO market_NN generic_JJ omeprazole_NN ._.
During_IN 2003_CD ,_, after_IN Mylan_NNP commenced_VBD commercial_JJ sale_NN of_IN its_PRP$ product_NN ,_, AstraZeneca_NNP filed_VBD suit_NN against_IN Laboratorios_NNP Esteve_NNP ,_, SA_NNP and_CC Esteve_NNP Quimica_NNP ,_, SA_NNP ,_, manufacturers_NNS of_IN the_DT omeprazole_JJ product_NN to_TO be_VB distributed_VBN in_IN the_DT US_NNP by_IN Mylan_NNP ._.
In_IN 2003_CD and_CC 2004_CD ,_, Lek_NNP ,_, Apotex_NNP and_CC Impax_NNP all_DT began_VBD commercial_JJ sales_NNS of_IN their_PRP$ generic_JJ omeprazole_NN products_NNS ._.
In_IN July_NNP 2004_CD ,_, Lek_NNP filed_VBD a_DT motion_NN for_IN summary_NN judgement_NN of_IN noninfringement_NN ._.
In_IN January_NNP 2005_CD ,_, AstraZeneca_NNP filed_VBD suit_NN against_IN Teva_NNP Pharmaceutical_NNP Industries_NNPS Ltd._NNP and_CC Teva_NNP Pharmaceuticals_NNP USA_NNP ,_, Inc._NNP which_WDT are_VBP marketing_VBG and_CC selling_VBG Impaxs_NNP omeprazole_NN products_NNS ._.
The_DT Teva_NNP case_NN was_VBD stayed_VBN in_IN June_NNP 2005_CD until_IN liability_NN issues_NNS in_IN the_DT Impax_NNP action_NN are_VBP resolved_VBN ._.
AstraZeneca_NNP has_VBZ made_VBN claims_NNS for_IN damages_NNS against_IN each_DT of_IN the_DT selling_NN defendants_NNS ._.
Anti-trust_NN and_CC non-infringement_JJ counterclaims_NNS have_VBP been_VBN filed_VBN by_IN Andrx_NNP ,_, Apotex_NNP Torpharm_NNP ,_, Impax_NNP ,_, Eon_NNP and_CC Lek_NNP ._.
All_DT defendants_NNS except_IN Lek_NNP have_VBP also_RB raised_VBN invalidity_NN and_CC unenforceability_NN counterclaims_NNS ._.
The_DT anti-trust_JJ counterclaims_NNS ,_, as_RB well_RB as_IN AstraZenecas_NNP claims_NNS for_IN damages_NNS ,_, have_VBP been_VBN stayed_VBN pending_VBG resolution_NN of_IN the_DT patent_NN liability_NN issues_NNS ._.
The_DT cases_NNS have_VBP been_VBN consolidated_VBN for_IN discovery_NN before_IN ,_, or_CC are_VBP directly_RB assigned_VBN to_TO ,_, Judge_NNP Jones_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP ._.
All_DT discovery_NN in_IN these_DT cases_NNS was_VBD completed_VBN in_IN February_NNP 2005_CD ._.
Briefing_NN on_IN the_DT summary_NN judgement_NN motion_NN filed_VBN by_IN Lek_NNP and_CC 14_CD additional_JJ motions_NNS for_IN summary_NN judgement_NN was_VBD completed_VBN in_IN July_NNP 2005_CD ._.
All_DT of_IN the_DT defendants_NNS motions_NNS for_IN summary_NN judgement_NN were_VBD denied_VBN in_IN January_NNP 2006_CD ._.
In_IN July_NNP 2005_CD ,_, AstraZeneca_NNP filed_VBD suit_NN against_IN Ranbaxy_NNP Laboratories_NNPS Ltd._NNP ._.
Ranbaxy_NNP Inc._NNP and_CC Ranbaxy_NNP Pharmaceuticals_NNP ,_, Inc._NNP for_IN infringement_NN of_IN the505_CD and_CC 230_CD formulation_NN patents_NNS ._.
The_DT Ranbaxy_NNP case_NN has_VBZ been_VBN consolidated_VBN with_IN the_DT other_JJ omeprazole_NN patent_NN cases_NNS for_IN pre-trial_JJ purposes_NNS ._.
Judge_NNP Jones_NNP has_VBZ scheduled_VBN a_DT consolidated_JJ bench_NN trial_NN to_TO begin_VB in_IN March_NNP 2006_CD ._.
In_IN June_NNP and_CC July_NNP 2004_CD ,_, AstraZeneca_NNP applied_VBD in_IN France_NNP for_IN injunctions_NNS based_VBN on_IN its_PRP$ omeprazole_NN formulation_NN patent_NN against_IN six_CD companies_NNS for_IN marketing_NN generic_JJ omeprazole_NN ._.
In_IN August_NNP 2004_CD ,_, the_DT applications_NNS were_VBD rejected_VBN at_IN first_JJ instance_NN ._.
AstraZeneca_NNP appealed_VBD this_DT decision_NN and_CC in_IN March_NNP 2005_CD the_DT applications_NNS were_VBD rejected_VBN on_IN appeal_NN ._.
In_IN May_NNP 2004_CD ,_, AstraZeneca_NNP also_RB started_VBD legal_JJ proceedings_NNS against_IN the_DT same_JJ companies_NNS for_IN infringement_NN of_IN its_PRP$ omeprazole_NN formulation_NN patent_NN in_IN France_NNP ._.
These_DT proceedings_NNS have_VBP been_VBN consolidated_VBN with_IN a_DT case_NN challenging_VBG the_DT validity_NN of_IN the_DT patent_NN ,_, brought_VBN by_IN one_CD of_IN the_DT companies_NNS against_IN AstraZeneca_NNP ._.
No_DT date_NN has_VBZ yet_RB been_VBN set_VBN for_IN a_DT hearing_NN ._.
During_IN 2000_CD ,_, AstraZeneca_NNP was_VBD granted_VBN interlocutory_JJ injunctions_NNS based_VBN on_IN certain_JJ of_IN AstraZenecas_NNP omeprazole_NN patents_NNS against_IN the_DT generic_JJ company_NN ,_, Scandinavian_NNP AB_NNP Scand_NNP Pharm_NNP ,_, in_IN Denmark_NNP and_CC Norway_NNP ._.
In_IN October_NNP 2001_CD ,_, Oslo_NNP City_NNP Court_NNP in_IN Norway_NNP confirmed_VBD that_IN Scand_NNP Pharm_NNP had_VBD infringed_VBN AstraZenecas_NNP formulation_NN patent_NN for_IN omeprazole_NN ._.
At_IN the_DT same_JJ time_NN ,_, the_DT court_NN declared_VBD AstraZenecas_NNP formulation_NN patent_NN valid_JJ ._.
In_IN November_NNP 2004_CD ,_, these_DT findings_NNS were_VBD upheld_VBN by_IN the_DT Appeal_NNP Court_NNP ._.
As_IN a_DT result_NN of_IN the_DT Norwegian_JJ case_NN ,_, Scand_NNP Pharm_NNP can_MD not_RB sell_VB its_PRP$ omeprazole_JJ product_NN in_IN Norway_NNP ._.
Furthermore_RB ,_, it_PRP is_VBZ also_RB prevented_VBN from_IN selling_VBG its_PRP$ omeprazole_JJ product_NN in_IN Denmark_NNP pending_VBG the_DT outcome_NN of_IN the_DT main_JJ action_NN in_IN the_DT Danish_JJ case_NN ._.
If_IN the_DT final_JJ decision_NN in_IN this_DT case_NN is_VBZ against_IN AstraZeneca_NNP ,_, Scand_NNP Pharm_NNP may_MD claim_VB damages_NNS for_IN lost_VBN sales_NNS due_JJ to_TO the_DT interlocutory_JJ injunctions_NNS ._.
During_IN 2003_CD and_CC 2004_CD ,_, AstraZeneca_NNP was_VBD denied_VBN interlocutory_JJ injunctions_NNS based_VBN on_IN certain_JJ of_IN its_PRP$ omeprazole_NN patents_NNS against_IN Novartis_NNP Sverige_NNP AB_NNP and_CC ratiopharm_JJ AB_NNP in_IN Sweden_NNP and_CC Novartis_NNP Finland_NNP Oy_NNP and_CC ratiopharm_JJ Oy_NNP in_IN Finland_NNP ._.
An_DT interlocutory_JJ injunction_NN against_IN Biochemie_NNP Novartis_NNP Healthcare_NNP A_NNP S_NNP was_VBD granted_VBN in_IN Denmark_NNP during_IN 2003_CD ,_, based_VBN on_IN AstraZenecas_NNP omeprazole_NN formulation_NN patent_NN ._.
Also_RB during_IN 2003_CD ,_, the_DT District_NNP Court_NNP in_IN Norway_NNP found_VBD that_IN the_DT generic_JJ omeprazole_NN product_NN marketed_VBN by_IN ratiopharm_JJ AS_NNP did_VBD not_RB infringe_VB AstraZenecas_NNP omeprazole_JJ formulation_NN patent_NN ._.
This_DT judgement_NN was_VBD confirmed_VBN by_IN the_DT Norwegian_JJ Appeal_NNP Court_NNP in_IN October_NNP 2005_CD ._.
In_IN January_NNP 2006_CD ,_, the_DT Supreme_NNP Court_NNP in_IN Norway_NNP denied_VBD AstraZeneca_NNP leave_VBP to_TO appeal_VB ._.
In_IN December_NNP 2004_CD ,_, an_DT interlocutory_JJ injunction_NN against_IN Nomeco_NNP A_NNP S_NNP ,_, a_DT Danish_JJ distributor_NN of_IN a_DT generic_JJ omeprazole_NN product_NN from_IN ratiopharm_NN ,_, was_VBD granted_VBN in_IN Denmark_NNP based_VBN on_IN AstraZenecas_NNP omeprazole_NN formulation_NN patent_NN ._.
The_DT case_NN was_VBD heard_VBN on_IN appeal_NN in_IN November_NNP and_CC December_NNP 2005_CD ._.
The_DT courts_NNS decision_NN is_VBZ anticipated_VBN in_IN February_NNP 2006_CD ._.
AstraZeneca_NNP continues_VBZ to_TO be_VB involved_VBN in_IN numerous_JJ proceedings_NNS in_IN Canada_NNP involving_VBG Reddy_NNP Cheminor_NNP and_CC Apotex_NNP ._.
These_DT cases_NNS relate_VBP to_TO omeprazole_VB capsules_NNS or_CC omeprazole_NN magnesium_NN tablets_NNS and_CC involve_VB various_JJ patents_NNS ._.
Apotex_NNP launched_VBD a_DT generic_JJ omeprazole_NN capsule_NN product_NN in_IN Canada_NNP in_IN January_NNP 2004_CD ._.
Following_VBG this_DT launch_NN ,_, AstraZeneca_NNP commenced_VBD judicial_JJ review_NN proceedings_NNS seeking_VBG to_TO quash_VB Apotexs_NNP notice_NN of_IN compliance_NN marketing_NN approval_NN and_CC AstraZeneca_NNP sued_VBD Apotex_NNP in_IN July_NNP 2004_CD alleging_VBG infringement_NN of_IN its_PRP$ formulation_NN patents_NNS by_IN Apotexs_NNP omeprazole_NN capsules_NNS ._.
In_IN May_NNP 2005_CD ,_, the_DT Canadian_NNP Federal_NNP Court_NNP of_IN Appeal_NNP quashed_VBD Apotexs_NNP notice_NN of_IN compliance_NN marketing_NN approval_NN ,_, overruling_VBG the_DT first_JJ instance_NN decision_NN in_IN September_NNP 2004_CD ,_, which_WDT went_VBD against_IN AstraZeneca_NNP ._.
In_IN June_NNP 2005_CD ,_, the_DT Canadian_NNP Federal_NNP Court_NNP of_IN Appeal_NNP granted_VBD Apotexs_NNP motion_NN for_IN a_DT stay_NN of_IN the_DT courts_NNS decision_NN to_TO quash_VB the_DT notice_NN of_IN compliance_NN ,_, pending_VBG an_DT application_NN by_IN Apotex_NNP for_IN leave_NN to_TO appeal_VB to_TO the_DT Supreme_NNP Court_NNP of_IN Canada_NNP ._.
The_DT Supreme_NNP Court_NNP of_IN Canada_NNP has_VBZ granted_VBN Apotex_NNP leave_VBP to_TO appeal_VB and_CC the_DT appeal_NN is_VBZ tentatively_RB scheduled_VBN to_TO be_VB heard_VBN in_IN May_NNP 2006_CD ._.
The_DT Supreme_NNP Court_NNP has_VBZ also_RB continued_VBN the_DT stay_NN granted_VBN by_IN the_DT Federal_NNP Court_NNP of_IN Appeal_NNP ,_, thereby_RB allowing_VBG Apotex_NNP to_TO continue_VB selling_VBG its_PRP$ omeprazole_NN capsules_NNS pending_VBG a_DT decision_NN by_IN the_DT Supreme_NNP Court_NNP on_IN Apotexs_NNP appeal_NN ._.
In_IN January_NNP 2006_CD ,_, AstraZeneca_NNP Canada_NNP Inc._NNP was_VBD served_VBN with_IN a_DT claim_NN in_IN the_DT Federal_NNP Court_NNP of_IN Canada_NNP for_IN payment_NN of_IN an_DT undetermined_JJ sum_NN based_VBN on_IN damages_NNS allegedly_RB suffered_VBN by_IN Apotex_NNP due_JJ to_TO the_DT delay_NN from_IN January_NNP 2002_CD to_TO January_NNP 2004_CD in_IN the_DT issuance_NN to_TO Apotex_NNP of_IN a_DT notice_NN of_IN compliance_NN marketing_NN approval_NN in_IN Canada_NNP for_IN its_PRP$ 20mg_JJ omeprazole_NN capsule_NN product_NN ._.
AstraZeneca_NNP believes_VBZ the_DT claim_NN is_VBZ without_IN merit_NN and_CC intends_VBZ to_TO defend_VB it_PRP and_CC to_TO pursue_VB its_PRP$ already_RB pending_VBG patent_NN infringement_NN action_NN against_IN Apotex_NNP vigorously_RB ._.
Financial_NNP Statements_NNP 121_CD 25_CD COMMITMENTS_NNS AND_CC CONTINGENT_JJ LIABILITIES_NNS CONTINUED_VBD In_IN February_NNP 2000_CD ,_, the_DT European_JJ Commission_NNP commenced_VBD an_DT investigation_NN relating_VBG to_TO certain_JJ omeprazole_NN intellectual_JJ property_NN rights_NNS ,_, and_CC associated_VBN regulatory_JJ and_CC patent_NN infringement_NN litigation_NN ._.
The_DT investigation_NN is_VBZ pursuant_JJ to_TO Article_NNP 82_CD of_IN the_DT EC_NNP Treaty_NNP ,_, which_WDT prohibits_VBZ an_DT abuse_NN of_IN a_DT dominant_JJ position_NN ._.
The_DT investigation_NN was_VBD precipitated_VBN by_IN a_DT complaint_NN by_IN a_DT party_NN to_TO a_DT number_NN of_IN patent_NN and_CC other_JJ proceedings_NNS involving_VBG AstraZeneca_NNP ._.
AstraZeneca_NNP has_VBZ ,_, in_IN accordance_NN with_IN its_PRP$ corporate_JJ policy_NN ,_, co-operated_JJ with_IN the_DT Commission_NNP ._.
In_IN July_NNP 2003_CD ,_, the_DT Commission_NNP served_VBD a_DT Statement_NN of_IN Objections_NNS on_IN AstraZeneca_NNP ,_, referring_VBG to_TO alleged_VBN infringements_NNS regarding_VBG the_DT obtaining_VBG of_IN supplementary_JJ protection_NN certificates_NNS for_IN omeprazole_NN in_IN certain_JJ European_JJ countries_NNS :_: and_CC regarding_VBG AstraZenecas_NNP replacement_NN of_IN omeprazole_NN capsules_NNS by_IN omeprazole_NN MUPS_NNP tablets_NNS and_CC withdrawal_NN of_IN capsule_NN marketing_NN authorisations_NNS in_IN three_CD European_JJ countries_NNS ._.
AstraZeneca_NNP replied_VBD fully_RB to_TO the_DT Commission_NNP ,_, explaining_VBG why_WRB its_PRP$ actions_NNS were_VBD in_IN AstraZenecas_NNP view_NN lawful_JJ ._.
An_DT oral_JJ hearing_NN took_VBD place_NN in_IN February_NNP 2004_CD ._.
In_IN June_NNP 2005_CD ,_, the_DT European_NNP Commission_NNP notified_VBD AstraZeneca_NNP PLC_NNP and_CC AstraZeneca_NNP AB_NNP of_IN its_PRP$ Decision_NN to_TO impose_VB fines_NNS totalling60m_VB on_IN the_DT companies_NNS for_IN infringement_NN of_IN European_JJ competition_NN law_NN Article_NNP 82_CD of_IN the_DT EC_NNP Treaty_NNP and_CC Article_NNP 54_CD of_IN the_DT EEA_NNP Agreement_NNP ._.
The_DT Commission_NNP alleges_VBZ that_IN the_DT companies_NNS abused_VBD their_PRP$ dominant_JJ positions_NNS in_IN the_DT periods_NNS between_IN 1993_CD and_CC 2000_CD by_IN making_VBG a_DT pattern_NN of_IN misleading_JJ representations_NNS before_IN the_DT patent_NN offices_NNS and_CC or_CC courts_NNS in_IN Belgium_NNP ,_, Denmark_NNP ,_, Germany_NNP ,_, the_DT Netherlands_NNP ,_, Norway_NNP and_CC the_DT UK_NNP in_IN regard_NN to_TO obtaining_VBG supplementary_JJ protection_NN certificates_NNS for_IN omeprazole_NN :_: and_CC by_IN requesting_VBG the_DT surrender_NN of_IN market_NN authorisations_NNS for_IN omeprazole_JJ capsules_NNS in_IN Denmark_NNP ,_, Norway_NNP and_CC Sweden_NNP ,_, combined_VBN with_IN withdrawal_NN from_IN these_DT countries_NNS of_IN omeprazole_NN capsules_NNS and_CC the_DT launch_NN of_IN omeprazole_NN MUPS_NNP tablets_NNS ._.
AstraZeneca_NNP does_VBZ not_RB accept_VB the_DT Commissions_NNS Decision_NN and_CC has_VBZ appealed_VBN it_PRP to_TO the_DT Court_NNP of_IN First_NNP Instance_NNP ._.
AstraZeneca_NNP denies_VBZ that_IN it_PRP had_VBD a_DT dominant_JJ position_NN or_CC that_IN it_PRP was_VBD engaged_VBN in_IN the_DT behaviors_NNS as_IN characterised_VBN by_IN the_DT Commission_NNP ._.
In_IN the_DT meantime_NN ,_, the_DT fine_NN was_VBD fully_RB provided_VBN for_IN in_IN the_DT half_NN year_NN results_NNS through_IN a_DT charge_NN to_TO operating_VBG profit_NN of_IN $_$ 75m_CD ._.
It_PRP is_VBZ alleged_VBN by_IN the_DT Commission_NNP that_IN these_DT activities_NNS had_VBD the_DT effect_NN of_IN hindering_VBG the_DT entry_NN of_IN the_DT generic_JJ version_NN of_IN Losec_NNP and_CC parallel_JJ trade_NN ._.
It_PRP is_VBZ possible_JJ that_IN third_JJ parties_NNS could_MD seek_VB damages_NNS for_IN alleged_JJ losses_NNS arising_VBG from_IN this_DT matter_NN ._.
Any_DT such_JJ claims_NNS would_MD be_VB vigorously_RB resisted_VBN ._.
Nexium_NNP esomeprazole_NN AstraZeneca_NNP entities_NNS have_VBP been_VBN sued_VBN in_IN various_JJ state_NN and_CC federal_JJ courts_NNS in_IN the_DT US_NNP in_IN purported_JJ representative_NN and_CC class_NN actions_NNS involving_VBG the_DT marketing_NN of_IN Nexium_NNP esomeprazole_NN ._.
These_DT actions_NNS generally_RB allege_VBP that_IN AstraZenecas_NNP promotion_NN and_CC advertising_NN of_IN Nexium_NNP to_TO physicians_NNS and_CC consumers_NNS is_VBZ unfair_JJ ,_, unlawful_JJ and_CC deceptive_JJ conduct_NN ,_, particularly_RB as_IN the_DT promotion_NN relates_VBZ to_TO comparisons_NNS of_IN Nexium_NNP with_IN Prilosec_NNP ._.
They_PRP also_RB allege_VBP that_IN AstraZenecas_NNP conduct_NN relating_VBG to_TO the_DT pricing_NN of_IN Nexium_NNP was_VBD unfair_JJ ,_, unlawful_JJ and_CC deceptive_JJ ._.
The_DT plaintiffs_NNS allege_VBP claims_NNS under_IN various_JJ state_NN consumer_NN protection_NN ,_, unfair_JJ practices_NNS and_CC false_JJ advertising_NN laws_NNS ._.
The_DT plaintiffs_NNS in_IN these_DT cases_NNS seek_VBP remedies_NNS that_WDT include_VBP restitution_NN ,_, disgorgement_NN of_IN profits_NNS ,_, damages_NNS ,_, punitive_JJ damages_NNS ,_, injunctive_JJ relief_NN ,_, attorneys_NNS fees_NNS and_CC costs_NNS of_IN suit_NN ._.
The_DT first_JJ action_NN was_VBD brought_VBN in_IN 2004_CD in_IN the_DT Superior_NNP Court_NNP of_IN the_DT State_NN of_IN California_NNP for_IN the_DT County_NNP of_IN Los_NNP Angeles_NNP by_IN the_DT AFL-CIO_NNP ,_, two_CD unincorporated_JJ associations_NNS and_CC an_DT individual_NN on_IN behalf_NN of_IN themselves_PRP ,_, the_DT general_JJ public_NN and_CC a_DT class_NN of_IN California_NNP consumers_NNS ,_, third_JJ party_NN payers_NNS ,_, cash_NN payers_NNS and_CC those_DT making_VBG co-pay_NN ._.
A_DT second_JJ action_NN was_VBD filed_VBN in_IN the_DT same_JJ court_NN on_IN behalf_NN of_IN a_DT similar_JJ putative_JJ class_NN of_IN consumers_NNS ._.
Actions_NNS making_VBG substantially_RB similar_JJ allegations_NNS were_VBD filed_VBN in_IN 2004_CD and_CC 2005_CD on_IN behalf_NN of_IN putative_JJ classes_NNS of_IN consumers_NNS ,_, third_JJ party_NN payers_NNS ,_, purchasers_NNS and_CC labor_NN management_NN trust_NN funds_NNS in_IN the_DT Circuit_NNP Court_NNP of_IN Searcy_NNP County_NNP ,_, Arkansas_NNP :_: in_IN the_DT Superior_NNP Court_NNP of_IN the_DT State_NN of_IN Delaware_NNP in_IN and_CC for_IN New_NNP Castle_NNP County_NNP :_: in_IN the_DT Superior_NNP Court_NNP of_IN Massachusetts_NNP in_IN Boston_NNP :_: in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Delaware_NNP :_: and_CC in_IN the_DT Circuit_NNP Court_NNP of_IN the_DT 11th_JJ Judicial_NNP Court_NNP in_IN and_CC for_IN Miami-Dade_NNP County_NNP ,_, Florida_NNP ._.
In_IN September_NNP 2005_CD ,_, the_DT court_NN in_IN California_NNP issued_VBD a_DT ruling_NN on_IN AstraZenecas_NNP demurrer_NN and_CC motion_NN to_TO strike_VB in_IN the_DT two_CD California_NNP actions_NNS ._.
The_DT court_NN granted_VBD AstraZenecas_NNP motion_NN with_IN respect_NN to_TO the_DT associational_JJ plaintiffs_NNS and_CC denied_VBD the_DT motion_NN with_IN respect_NN to_TO the_DT individual_JJ plaintiffs_NNS ,_, allowing_VBG the_DT cases_NNS of_IN the_DT individuals_NNS to_TO proceed_VB ._.
In_IN October_NNP 2005_CD ,_, the_DT court_NN in_IN Massachusetts_NNP issued_VBD an_DT order_NN denying_VBG AstraZenecas_NNP motion_NN to_TO dismiss_VB ._.
In_IN November_NNP 2005_CD ,_, the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Delaware_NNP issued_VBD an_DT order_NN granting_VBG AstraZenecas_NNP motion_NN to_TO dismiss_VB the_DT consolidated_JJ class_NN action_NN complaint_NN in_IN the_DT three_CD consolidated_JJ Delaware_NNP actions_NNS ._.
AstraZeneca_NNP denies_VBZ the_DT allegations_NNS and_CC is_VBZ vigorously_RB defending_VBG each_DT of_IN these_DT actions_NNS ._.
In_IN November_NNP 2003_CD ,_, the_DT European_JJ Patent_NNP Office_NNP ruled_VBD that_IN the_DT European_JJ substance_NN patent_NN covering_VBG magnesium_NN esomeprazole_NN ,_, the_DT active_JJ pharmaceutical_JJ ingredient_NN in_IN Nexium_NNP ,_, is_VBZ valid_JJ ._.
The_DT patent_NN ,_, which_WDT expires_VBZ in_IN May_NNP 2014_CD ,_, was_VBD challenged_VBN by_IN the_DT generic_JJ manufacturer_NN ratiopharm_NN ._.
The_DT European_JJ Patent_NNP Office_NNP ruling_NN has_VBZ been_VBN appealed_VBN by_IN ratiopharm_NN ._.
It_PRP is_VBZ not_RB anticipated_VBN that_IN the_DT appeal_NN will_MD be_VB heard_VBN before_IN the_DT end_NN of_IN 2006_CD ._.
In_IN October_NNP 2004_CD ,_, AstraZeneca_NNP LP_NNP filed_VBD suit_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Delaware_NNP seeking_VBG declaratory_JJ judgement_NN that_IN its_PRP$ Better_NNP is_VBZ Better_RBR campaign_NN for_IN Nexium_NNP is_VBZ not_RB false_JJ or_CC misleading_JJ advertising_NN in_IN violation_NN of_IN section_NN 43_CD a_DT of_IN the_DT Lanham_NNP Act_NNP ,_, a_DT federal_JJ statute_NN governing_VBG false_JJ advertising_NN claims_NNS ._.
The_DT action_NN was_VBD taken_VBN in_IN response_NN to_TO a_DT letter_NN from_IN TAP_NNP Pharmaceuticals_NNP ,_, Inc._NNP demanding_VBG that_IN AstraZeneca_NNP immediately_RB withdraw_VB the_DT television_NN commercial_NN and_CC other_JJ components_NNS of_IN the_DT direct-to-consumer_NN advertising_NN campaign_NN for_IN Nexium_NNP on_IN the_DT basis_NN that_IN they_PRP allegedly_RB violated_VBD the_DT statute_NN ._.
In_IN November_NNP 2004_CD ,_, TAP_NNP requested_VBD expedited_VBN consideration_NN of_IN the_DT case_NN by_IN filing_VBG a_DT motion_NN for_IN a_DT preliminary_JJ injunction_NN and_CC in_IN December_NNP 2004_CD ,_, the_DT court_NN denied_VBD the_DT request_NN for_IN a_DT preliminary_JJ injunction_NN ._.
The_DT case_NN is_VBZ scheduled_VBN to_TO be_VB tried_VBN in_IN the_DT second_JJ or_CC third_JJ quarter_NN of_IN 2006_CD ._.
In_IN October_NNP 2005_CD ,_, AstraZeneca_NNP received_VBD a_DT notice_NN from_IN Ranbaxy_NNP Pharmaceuticals_NNP ,_, Inc._NNP that_IN Ranbaxy_NNP Laboratories_NNP Limited_NNP had_VBD submitted_VBN an_DT Abbreviated_NNP New_NNP Drug_NNP Application_NNP to_TO the_DT US_NNP FDA_NNP for_IN esomeprazole_NN magnesium_NN delayed-release_NN capsules_NNS ,_, 20mg_JJ and_CC 40mg_JJ ._.
The_DT ANDA_NNP contained_VBD paragraph_NN IV_NNP certifications_NNS of_IN invalidity_NN and_CC or_CC non-infringement_JJ in_IN respect_NN of_IN certain_JJ AstraZeneca_NNP US_NNP patents_NNS listed_VBN in_IN the_DT FDAs_NNP Orange_NNP Book_NNP with_IN reference_NN to_TO Nexium_NNP ._.
In_IN November_NNP 2005_CD ,_, AstraZeneca_NNP commenced_VBD wilful_JJ infringement_NN patent_NN litigation_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP against_IN Ranbaxy_NNP Pharmaceuticals_NNP ,_, Inc._NNP and_CC its_PRP$ affiliates_NNS in_IN response_NN to_TO Ranbaxys_NNP paragraph_NN IV_NNP certifications_NNS regarding_VBG Nexium_NNP ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC 122_CD Form_NN 20-F_JJ Information_NN 2005_CD NOTES_NNS TO_TO THE_DT FINANCIAL_NNP STATEMENTS_NNS CONTINUED_VBD 25_CD COMMITMENTS_NNS AND_CC CONTINGENT_JJ LIABILITIES_NNS CONTINUED_VBD In_IN January_NNP 2006_CD ,_, AstraZeneca_NNP received_VBD a_DT notice_NN from_IN IVAX_NNP Pharmaceuticals_NNP Inc._NNP that_WDT IVAX_NNP Corporation_NNP had_VBD submitted_VBN an_DT ANDA_NNP to_TO th_VB e_SYM US_PRP FDA_NNP for_IN esomeprazole_NN magnesium_NN delayed-release_NN capsules_NNS ,_, 20mg_JJ and_CC 40mg_JJ ._.
IVAX_NNP also_RB certified_VBD in_IN respect_NN of_IN certain_JJ other_JJ AstraZeneca_NNP US_NNP patents_NNS listed_VBN in_IN the_DT Orange_NNP Book_NNP with_IN reference_NN to_TO Nexium_NNP that_IN IVAX_NNP will_MD not_RB launch_VB its_PRP$ product_NN prior_RB to_TO the_DT expiry_NN of_IN those_DT patents_NNS ,_, the_DT latter_NN of_IN which_WDT expires_VBZ in_IN October_NNP 2007_CD ._.
The_DT 45_CD day_NN time_NN period_NN within_IN which_WDT AstraZeneca_NNP can_MD commence_VB a_DT patent_NN infringement_NN lawsuit_NN against_IN IVAX_NNP that_WDT would_MD automatically_RB stay_VB ,_, or_CC bar_NN ,_, the_DT FDA_NNP from_IN approving_VBG IVAX_NNP s_VBZ ANDA_NNP for_IN 30_CD months_NNS or_CC u_JJ ntil_NN an_DT adverse_JJ court_NN decision_NN ,_, whichever_WDT occurs_VBZ earlier_JJR expires_VBZ in_IN March_NNP 2006_CD ._.
AstraZeneca_NNP continues_VBZ to_TO have_VB full_JJ confidence_NN in_IN and_CC will_MD vigorously_RB defend_VB and_CC enforce_VB its_PRP$ intellectual_JJ property_NN protecting_VBG Nexium_NNP ._.
Nolvadex_NNP tamoxifen_NN AstraZeneca_NNP is_VBZ a_DT co-defendant_NN with_IN Barr_NNP Laboratories_NNPS ,_, Inc._NNP in_IN numerous_JJ purported_JJ class_NN actions_NNS filed_VBN in_IN federal_JJ and_CC state_NN courts_NNS throughout_IN the_DT US_NNP ._.
All_DT of_IN the_DT state_NN court_NN actions_NNS were_VBD removed_VBN to_TO federal_JJ court_NN and_CC have_VBP been_VBN consolidated_JJ ,_, along_IN with_IN all_DT of_IN the_DT cases_NNS originally_RB filed_VBN in_IN the_DT federal_JJ courts_NNS ,_, in_IN a_DT federal_JJ multi-district_JJ litigation_NN proceeding_VBG pending_VBG in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN New_NNP York_NNP ._.
Some_DT of_IN the_DT cases_NNS were_VBD filed_VBN by_IN plaintiffs_NNS representing_VBG a_DT putative_JJ class_NN of_IN consumers_NNS who_WP purchased_VBD tamoxifen_NN ._.
The_DT other_JJ cases_NNS were_VBD filed_VBN on_IN behalf_NN of_IN a_DT putative_JJ class_NN of_IN third_JJ party_NN payers_NNS including_VBG health_NN maintenance_NN organizations_NNS ,_, insurers_NNS and_CC other_JJ managed_VBN care_NN providers_NNS and_CC health_NN plans_NNS that_WDT have_VBP reimbursed_VBN or_CC otherwise_RB paid_VBN for_IN prescriptions_NNS of_IN tamoxifen_NN ._.
The_DT plaintiffs_NNS allege_VBP that_IN they_PRP paid_VBD supra-competitive_JJ and_CC monopolistic_JJ prices_NNS for_IN tamoxifen_NN as_IN a_DT result_NN of_IN the_DT settlement_NN of_IN patent_NN litigation_NN between_IN Zeneca_NNP and_CC Barr_NNP in_IN 1993_CD ._.
The_DT plaintiffs_NNS seek_VBP injunctive_JJ relief_NN ,_, treble_JJ damages_NNS under_IN the_DT antitrust_JJ laws_NNS ,_, disgorgement_NN and_CC restitution_NN ._.
In_IN April_NNP 2002_CD ,_, AstraZeneca_NNP filed_VBD a_DT motion_NN to_TO dismiss_VB the_DT cases_NNS for_IN failure_NN to_TO state_VB a_DT cause_NN of_IN action_NN ._.
In_IN May_NNP 2003_CD ,_, the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN New_NNP York_NNP granted_VBD AstraZenecas_NNP motion_NN to_TO dismiss_VB ._.
The_DT plaintiffs_NNS appealed_VBD the_DT decision_NN ._.
In_IN November_NNP 2005_CD ,_, the_DT US_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Second_NNP Circuit_NNP affirmed_VBD the_DT District_NNP Courts_NNPS decision_NN ._.
The_DT plaintiffs_NNS have_VBP moved_VBN for_IN re-hearing_NN by_IN the_DT original_JJ panel_NN of_IN judges_NNS in_IN the_DT case_NN and_CC re-hearing_NN by_IN a_DT panel_NN of_IN all_DT of_IN the_DT judges_NNS on_IN the_DT US_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Second_NNP Circuit_NNP ._.
Pulmicort_NNP Respules_NNP budesonide_NN inhalation_NN suspension_NN In_IN September_NNP 2005_CD ,_, AstraZeneca_NNP received_VBD a_DT notice_NN from_IN IVAX_NNP Pharmaceuticals_NNP Inc._NNP that_WDT IVAX_NNP had_VBD submitted_VBN an_DT Abbreviated_NNP New_NNP Drug_NNP App_NNP lication_NN to_TO the_DT US_NNP FDA_NNP for_IN a_DT budesonide_NN inhalation_NN suspension_NN containing_VBG a_DT paragraph_NN IV_NNP certification_NN and_CC alleging_VBG invalidity_NN and_CC non-infringement_NN in_IN respect_NN of_IN certain_JJ of_IN AstraZenecas_NNP patents_NNS relating_VBG to_TO budesonide_VB inhalation_NN suspension_NN ._.
In_IN October_NNP 2005_CD ,_, AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN IVAX_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP ._.
In_IN December_NNP 2005_CD ,_, IVAX_NNP responded_VBD and_CC filed_VBD counterclaims_NNS alleging_VBG no_DT n-infringement_NN and_CC invalidity_NN ._.
In_IN January_NNP 2006_CD ,_, AstraZeneca_NNP filed_VBD an_DT Amended_JJ Complaint_NN ,_, withdrawing_VBG averments_NNS as_IN to_TO the_DT infringement_NN of_IN one_CD of_IN the_DT patents-in-suit_NN ._.
AstraZeneca_NNP continues_VBZ to_TO have_VB full_JJ confidence_NN in_IN and_CC will_MD vigorously_RB defend_VB and_CC enforce_VB its_PRP$ intellectual_JJ property_NN protecting_VBG Pulmicort_NNP Respules_NNP ._.
Seroquel_NNP quetiapine_NN fumarate_NN AstraZeneca_NNP PLC_NNP and_CC AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP were_VBD named_VBN as_IN defendants_NNS in_IN the_DT case_NN of_IN Susan_NNP Zehel-Miller_NNP et_FW al._FW ._.
v._CC AstraZenaca_NNP -LRB-_-LRB- sic_JJ -RRB-_-RRB- ,_, AstraZenaca_NNP Pharmaceuticals_NNP ,_, LP_NNP -LRB-_-LRB- sic_JJ -RRB-_-RRB- ,_, a_DT putative_JJ class_NN action_NN suit_NN filed_VBN in_IN August_NNP 2003_CD in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Middl_NNP e_SYM District_NNP of_IN Florida_NNP on_IN behalf_NN of_IN a_DT purported_JJ class_NN consisting_VBG of_IN all_DT persons_NNS in_IN the_DT US_NNP who_WP purchased_VBD and_CC or_CC used_VBN Seroquel_NNP contending_VBG that_IN AstraZeneca_NNP failed_VBD to_TO provide_VB adequate_JJ warnings_NNS in_IN connection_NN with_IN an_DT alleged_JJ association_NN between_IN Seroquel_NNP and_CC the_DT onset_NN of_IN diabetes_NN ._.
In_IN the_DT first_JJ quarter_NN of_IN 2005_CD ,_, subsequent_JJ to_TO a_DT 2004_CD court_NN decision_NN denying_VBG class_NN certification_NN in_IN this_DT matter_NN ,_, the_DT case_NN was_VBD dismissed_VBN with_IN prejudice_NN ._.
A_DT second_JJ Seroquel_NNP lawsuit_NN involving_VBG a_DT minor_JJ who_WP claimed_VBD to_TO have_VB developed_VBN diabetes_NN mellitus_NN as_IN a_DT result_NN of_IN using_VBG Seroquel_NNP was_VBD also_RB dismissed_VBN with_IN prejudice_NN in_IN December_NNP 2005_CD ,_, approximately_RB one_CD week_NN before_IN oral_JJ argument_NN on_IN AstraZenecas_NNP motion_NN for_IN summary_NN judgement_NN was_VBD scheduled_VBN to_TO take_VB place_NN ._.
Since_IN 2003_CD ,_, AstraZeneca_NNP has_VBZ been_VBN served_VBN with_IN approximately_RB 60_CD lawsuits_NNS in_IN the_DT US_NNP in_IN which_WDT plaintiffs_NNS have_VBP contended_VBN that_IN they_PRP developed_VBD diabetes_NN or_CC other_JJ allegedly_RB related_JJ injuries_NNS as_IN a_DT result_NN of_IN taking_VBG Seroquel_NNP and_CC or_CC other_JJ atypical_JJ anti-psychotics_NNS made_VBN by_IN other_JJ pharmaceutical_JJ companies_NNS ._.
About_IN 40_CD of_IN these_DT cases_NNS were_VBD filed_VBN in_IN Missouri_NNP in_IN August_NNP 2005_CD ,_, days_NNS before_IN Missouris_NNP tort_NN reform_NN laws_NNS became_VBD effective_JJ ._.
Eli_NNP Lilly_NNP ,_, the_DT maker_NN of_IN olanzapine_NN ,_, is_VBZ a_DT defendant_NN in_IN the_DT majority_NN of_IN the_DT cases_NNS served_VBD on_IN AstraZeneca_NNP ._.
Janssen_NNP Pharmaceutica_NNP and_CC Bristol-Myers_NNP Squibb_NNP are_VBP also_RB defending_VBG a_DT number_NN of_IN them_PRP ._.
AstraZeneca_NNP is_VBZ also_RB aware_JJ of_IN more_JJR than_IN 100_CD other_JJ cases_NNS involving_VBG Seroquel_NNP that_WDT have_VBP recently_RB been_VBN filed_VBN in_IN California_NNP ,_, Delaware_NNP ,_, Illinois_NNP ,_, Louisiana_NNP ,_, Missouri_NNP ,_, New_NNP Jersey_NNP and_CC Texas_NNP ,_, but_CC these_DT have_VBP not_RB been_VBN served_VBN ._.
One_CD involves_VBZ a_DT putative_JJ nationwide_JJ class_NN action_NN complaint_NN ,_, which_WDT was_VBD recently_RB filed_VBN in_IN federal_JJ court_NN in_IN the_DT Southern_NNP District_NNP of_IN Illinois_NNP ._.
AstraZeneca_NNP has_VBZ seen_VBN this_DT complaint_NN and_CC it_PRP is_VBZ very_RB similar_JJ in_IN form_NN and_CC content_NN to_TO the_DT complaint_NN filed_VBN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Middle_NNP District_NNP of_IN Florida_NNP in_IN 2003_CD Susan_NNP Zehel-Miller_NNP et_FW al._FW ._.
v._CC AstraZenaca_NNP -LRB-_-LRB- sic_JJ -RRB-_-RRB- ,_, Astr_NNP aZenaca_NNP Pharmaceuticals_NNP LP_NNP ,_, -LRB-_-LRB- sic_JJ -RRB-_-RRB- ,_, described_VBN above_IN that_DT sought_VBD certification_NN of_IN a_DT nationwide_JJ class_NN of_IN Seroquel_NNP users_NNS and_CC others_NNS ,_, including_VBG individuals_NNS who_WP were_VBD alleged_VBN to_TO have_VB developed_VBN diabetes_NN as_IN a_DT result_NN of_IN using_VBG Seroquel_NNP ._.
The_DT federal_JJ court_NN in_IN Florida_NNP denied_VBD certification_NN of_IN the_DT class_NN in_IN the_DT Zehel-Miller_NNP case_NN ._.
In_IN early_JJ 2005_CD ,_, after_IN the_DT plaintiffs_NNS efforts_NNS in_IN that_DT case_NN to_TO secure_VB appellate_JJ relief_NN failed_VBD ,_, the_DT plaintiffs_NNS agreed_VBD to_TO a_DT voluntary_JJ dismissal_NN of_IN all_DT of_IN their_PRP$ claims_NNS with_IN prejudice_NN ._.
It_PRP is_VBZ possible_JJ that_IN plaintiffs_NNS lawyers_NNS are_VBP contemplating_VBG the_DT filing_NN of_IN potentially_RB numerous_JJ lawsuits_NNS against_IN AstraZeneca_NNP and_CC other_JJ manufacturers_NNS of_IN atypical_JJ anti-psychotics_NNS involving_VBG allegations_NNS of_IN diabetes_NN ._.
AstraZeneca_NNP intends_VBZ to_TO defend_VB vigorously_RB all_DT of_IN the_DT pending_VBG cases_NNS relating_VBG to_TO Seroquel_NNP ._.
In_IN September_NNP 2005_CD ,_, AstraZeneca_NNP received_VBD a_DT notice_NN from_IN Teva_NNP Pharmaceuticals_NNP USA_NNP that_IN Teva_NNP had_VBD submitted_VBN an_DT Abbreviated_NNP New_NNP Drug_NNP Application_NNP ANDA_NNP for_IN quetiapine_NN fumarate_NN tablets_NNS 25mg_JJ base_NN to_TO the_DT US_NNP FDA_NNP ._.
The_DT ANDA_NNP contained_VBD a_DT paragraph_NN IV_NNP certification_NN alleging_VBG invalidity_NN and_CC noninfringement_NN in_IN respect_NN of_IN AstraZenecas_NNP US_NNP patent_NN listed_VBN in_IN the_DT FDAs_NNP Orange_NNP Book_NNP with_IN reference_NN to_TO Seroquel_NNP ._.
In_IN November_NNP 2005_CD ,_, in_IN response_NN to_TO Tevas_NNP ANDA_NNP and_CC Tevas_NNP intent_NN to_TO market_VB a_DT generic_JJ version_NN of_IN Seroquel_NNP in_IN the_DT US_NNP prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patent_NN ,_, AstraZeneca_NNP filed_VBD a_DT lawsuit_NN against_IN Teva_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP for_IN wilful_JJ patent_NN infringement_NN ._.
AstraZeneca_NNP continues_VBZ to_TO have_VB full_JJ confidence_NN in_IN and_CC will_MD vigorously_RB defend_VB and_CC enforce_VB its_PRP$ intellectual_JJ property_NN protecting_VBG Seroquel_NNP ._.
Financial_NNP Statements_NNP 123_CD 25_CD COMMITMENTS_NNS AND_CC CONTINGENT_JJ LIABILITIES_NNS CONTINUED_VBD Symbicort_NNP budesonide_NN formoterol_NN In_IN March_NNP 2005_CD ,_, the_DT European_JJ Patent_NNP Office_NNP ruled_VBD that_IN the_DT European_JJ patent_NN covering_VBG the_DT combination_NN of_IN formoterol_NN and_CC budesonide_NN in_IN Symbicort_NNP is_VBZ valid_JJ ._.
The_DT patent_NN ,_, which_WDT expires_VBZ in_IN 2012_CD ,_, was_VBD challenged_VBN by_IN the_DT generic_JJ manufacturers_NNS Yamanouchi_NNP Europe_NNP BV_NNP ,_, Miat_NNP SpA_NNP ,_, Liconsa_NNP ,_, Chiesi_NNP Farmaceutici_NNP SpA_NNP ,_, Zambon_NNP Group_NNP SpA_NNP ,_, Generics_NNP UK_NNP Limited_NNP and_CC Norton_NNP Healthcare_NNP Ltd._NNP ._.
In_IN May_NNP 2005_CD ,_, the_DT European_JJ Patent_NNP Office_NNP ruled_VBD that_IN the_DT European_JJ patent_NN for_IN Symbicort_NNP in_IN the_DT treatment_NN of_IN chronic_JJ obstructive_JJ pulmonary_JJ disease_NN COPD_NNP is_VBZ valid_JJ ._.
The_DT patent_NN ,_, which_WDT expires_VBZ in_IN 2018_CD ,_, was_VBD challenged_VBN by_IN the_DT generic_JJ manufacturers_NNS Chiesi_NNP Farmaceutici_NNP SpA_NNP ,_, Norton_NNP Healthcare_NNP Ltd_NNP and_CC Generics_NNP UK_NNP Limited_NNP ._.
The_DT European_JJ Patent_NNP Office_NNP rulings_NNS relating_VBG to_TO both_DT the_DT combination_NN and_CC the_DT COPD_NNP European_NNP patents_NNS for_IN Symbicort_NNP have_VBP been_VBN appealed_VBN by_IN certain_JJ of_IN the_DT opponents_NNS in_IN the_DT proceedings_NNS ._.
It_PRP is_VBZ not_RB anticipated_VBN that_IN the_DT appeals_NNS will_MD be_VB heard_VBN before_IN 2007_CD ._.
In_IN February_NNP 2004_CD ,_, IVAX_NNP Pharmaceuticals_NNP UK_NNP Limited_NNP initiated_VBD proceedings_NNS against_IN AstraZeneca_NNP AB_NNP claiming_VBG that_IN the_DT UK_NNP parts_NNS of_IN t_NN he_PRP two_CD European_JJ patents_NNS related_VBN to_TO Symbicort_NNP were_VBD invalid_JJ ._.
In_IN May_NNP 2004_CD ,_, the_DT court_NN granted_VBD AstraZenecas_NNP application_NN for_IN a_DT stay_NN of_IN the_DT proceedings_NNS pending_VBG the_DT determination_NN of_IN the_DT parallel_JJ opposition_NN proceedings_NNS before_IN the_DT European_JJ Patent_NNP Office_NNP ,_, described_VBD above_IN ._.
In_IN April_NNP 2004_CD ,_, IVAX_NNP ini_FW tiated_VBN proceedings_NNS against_IN AstraZeneca_NNP AB_NNP in_IN relation_NN to_TO the_DT Republic_NNP of_IN Ireland_NNP claiming_VBG that_IN the_DT Irish_JJ parts_NNS of_IN the_DT two_CD European_JJ patents_NNS related_VBN to_TO Symbicort_NNP were_VBD invalid_JJ ._.
In_IN October_NNP 2004_CD ,_, the_DT court_NN granted_VBD AstraZenecas_NNP application_NN for_IN a_DT stay_NN of_IN proceedings_NNS pending_VBG the_DT final_JJ decision_NN of_IN the_DT European_JJ Patent_NNP Office_NNP and_CC its_PRP$ Boards_NNS of_IN Appeal_NNP in_IN the_DT opposition_NN proceedings_NNS ._.
Toprol-XL_JJ metoprolol_NN succinate_VB In_IN May_NNP 2003_CD ,_, AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN KV_NNP Pharmaceutical_NNP Company_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Missouri_NNP in_IN response_NN to_TO KVs_NNP notification_NN of_IN its_PRP$ intention_NN to_TO market_VB a_DT generic_JJ version_NN of_IN Toprol-XL_JJ tablets_NNS in_IN the_DT 200mg_JJ dose_NN prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patents_NNS covering_VBG the_DT substance_NN and_CC its_PRP$ formulation_NN ._.
In_IN response_NN to_TO later_RB similar_JJ notices_NNS from_IN KV_NNP related_VBN to_TO the_DT 25mg_JJ ,_, 50mg_JJ and_CC 100mg_JJ doses_NNS ,_, AstraZeneca_NNP filed_VBD further_JJ actions_NNS ._.
KV_NNP responded_VBD in_IN each_DT instance_NN and_CC filed_VBD counterclaims_NNS alleging_VBG non-infringement_JJ ,_, invalidity_NN and_CC unenforceability_NN of_IN the_DT listed_VBN patents_NNS ._.
In_IN February_NNP 2004_CD ,_, AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN Andrx_NNP Pharmaceuticals_NNP LLC_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Delaware_NNP in_IN response_NN to_TO Andrxs_NNP notification_NN of_IN its_PRP$ intention_NN to_TO market_VB a_DT generic_JJ version_NN of_IN Toprol-XL_JJ tablets_NNS in_IN the_DT 50mg_JJ dose_NN prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patents_NNS ._.
In_IN response_NN to_TO two_CD later_JJ similar_JJ notices_NNS from_IN Andrx_NNP related_VBN to_TO the_DT 25mg_JJ ,_, 100mg_JJ and_CC 200mg_JJ doses_NNS ,_, AstraZeneca_NNP filed_VBD two_CD additional_JJ patent_NN infringement_NN actions_NNS in_IN the_DT same_JJ court_NN ._.
In_IN each_DT instance_NN ,_, Andrx_NNP claimed_VBD that_IN each_DT of_IN the_DT listed_VBN patents_NNS is_VBZ invalid_JJ ,_, not_RB infringed_VBN and_CC unenforceable_JJ ._.
In_IN April_NNP 2004_CD ,_, AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN Eon_NNP Labs_NNPS Manufacturing_NNP Inc._NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Delaware_NNP in_IN response_NN to_TO Eons_NNS notification_NN of_IN its_PRP$ intention_NN to_TO market_NN generic_JJ versions_NNS of_IN Toprol-XL_JJ tablets_NNS in_IN the_DT 25mg_JJ ,_, 50mg_JJ ,_, 100mg_JJ and_CC 200mg_JJ doses_NNS prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patents_NNS ._.
In_IN its_PRP$ response_NN ,_, Eon_NNP alleged_VBD that_IN each_DT of_IN the_DT listed_VBN patents_NNS is_VBZ invalid_JJ ,_, not_RB infringed_VBN and_CC unenforceable_JJ ._.
Eon_NNP also_RB alleged_VBD that_IN the_DT filing_NN of_IN the_DT infringement_NN complaints_NNS ,_, as_RB well_RB as_IN other_JJ actions_NNS by_IN AstraZeneca_NNP ,_, constitutes_VBZ anti-competitive_JJ conduct_NN in_IN violation_NN of_IN US_NNP anti-trust_JJ laws_NNS ._.
Pursuant_JJ to_TO a_DT joint_JJ motion_NN of_IN AstraZeneca_NNP and_CC Eon_NNP these_DT anti-trust_JJ counts_NNS were_VBD severed_VBN from_IN the_DT case_NN and_CC stayed_VBD ,_, for_IN possible_JJ consideration_NN depending_VBG on_IN the_DT outcome_NN of_IN the_DT trial_NN of_IN the_DT patent_NN claims_NNS ._.
In_IN January_NNP 2005_CD ,_, AstraZeneca_NNP filed_VBD a_DT terminal_NN disclaimer_NN of_IN the_DT Toprol-XL_NNP patents-in-suit_NN over_IN one_CD of_IN the_DT other_JJ patents_NNS raised_VBN by_IN the_DT defendants_NNS ,_, which_WDT will_MD result_VB in_IN a_DT revision_NN of_IN the_DT expiration_NN date_NN of_IN the_DT Toprol-XL_NNP patents-in-suit_NN from_IN March_NNP 2008_CD to_TO September_NNP 2007_CD ._.
All_DT of_IN the_DT patent_NN litigation_NN relating_VBG to_TO Toprol-XL_NNP against_IN KV_NNP ,_, Andrx_NNP and_CC Eon_NNP was_VBD consolidated_VBN for_IN pre-trial_JJ discovery_NN purposes_NNS and_CC motion_NN practice_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Missouri_NNP ._.
The_DT defendants_NNS filed_VBD a_DT motion_NN for_IN summary_NN judgement_NN in_IN December_NNP 2004_CD alleging_VBG that_IN the_DT Toprol-XL_JJ patents_NNS are_VBP invalid_JJ due_JJ to_TO double_VB patenting_NN ._.
A_DT summary_NN judgement_NN motion_NN of_IN unenforceability_NN was_VBD filed_VBN by_IN the_DT defendants_NNS in_IN 2005_CD and_CC AstraZeneca_NNP filed_VBD summary_NN judgement_NN motions_NNS on_IN infringement_NN and_CC validity_NN in_IN 2005_CD ._.
Oral_JJ argument_NN on_IN all_DT of_IN the_DT pending_VBG summary_NN judgement_NN motions_NNS was_VBD heard_VBN in_IN November_NNP 2005_CD ._.
In_IN January_NNP 2006_CD ,_, the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Missouri_NNP issued_VBD a_DT ruling_NN finding_VBG that_IN the_DT two_CD patents-in-suit_NN are_VBP unenforceable_JJ based_VBN on_IN the_DT Companys_NNP inequitable_JJ conduct_NN in_IN the_DT prosecution_NN of_IN these_DT patents_NNS in_IN the_DT US_NNP Patent_NNP and_CC Trademark_NNP Office_NNP and_CC invalid_JJ ._.
AstraZeneca_NNP disagrees_VBZ with_IN and_CC is_VBZ disappointed_VBN by_IN these_DT conclusions_NNS ._.
It_PRP will_MD appeal_VB this_DT decision_NN to_TO the_DT US_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Federal_NNP Circuit_NNP ._.
None_NN of_IN the_DT Abbreviated_NNP New_NNP Drug_NNP Applications_NNS filed_VBN by_IN KV_NNP ,_, Andrx_NNP or_CC Eon_NNP has_VBZ received_VBN tentative_JJ approval_NN from_IN the_DT US_NNP Food_NNP and_CC Drug_NNP Administration_NNP ._.
Under_IN the_DT ANDA_NNP statute_NN ,_, the_DT January_NNP 2006_CD adverse_JJ decision_NN concerning_VBG the_DT validity_NN and_CC enforceability_NN of_IN the_DT AstraZeneca_NNP patents-in-suit_NN automatically_RB removes_VBZ any_DT stay_NN on_IN the_DT FDAs_NNS authority_NN to_TO grant_VB a_DT final_JJ approval_NN of_IN the_DT ANDAs_NNP ._.
In_IN January_NNP 2006_CD ,_, AstraZeneca_NNP was_VBD served_VBN with_IN a_DT complaint_NN filed_VBN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Delaware_NNP entitled_VBD Meijer_NNP ,_, Inc._NNP and_CC Meijer_NNP Distribution_NN ,_, Inc._NNP v._CC AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP ,_, AstraZeneca_NNP LP_NNP ,_, AstraZeneca_NNP AB_NNP and_CC Aktiebolaget_NNP Hassle_NNP ._.
The_DT complaint_NN is_VBZ a_DT putative_JJ class_NN action_NN that_WDT alleges_VBZ that_IN the_DT AstraZeneca_NNP defendants_NNS attempted_VBD to_TO illegally_RB maintain_VB monopoly_NN power_NN in_IN the_DT US_NNP over_IN Toprol-XL_NNP in_IN violation_NN of_IN the_DT Sherman_NNP Act_NNP through_IN the_DT listing_NN of_IN invalid_JJ and_CC unenforceable_JJ patents_NNS in_IN the_DT FDAs_NNP Orange_NNP Book_NNP and_CC the_DT enforcement_NN of_IN such_JJ patents_NNS through_IN litigation_NN against_IN generic_JJ manufacturers_NNS seeking_VBG to_TO market_NN metoprolol_NN succinate_NN ._.
The_DT complaint_NN seeks_VBZ treble_JJ damages_NNS based_VBN on_IN alleged_JJ overcharges_NNS to_TO the_DT putative_JJ class_NN of_IN plaintiffs_NNS ._.
The_DT lawsuit_NN is_VBZ based_VBN upon_IN the_DT finding_VBG described_VBN above_IN by_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Missouri_NNP in_IN the_DT consolidated_JJ litigation_NN against_IN KV_NNP ,_, Andrx_NNP and_CC Eon_NNP that_IN the_DT AstraZeneca_NNP patents_NNS relating_VBG to_TO Toprol-XL_NNP are_VBP invalid_JJ and_CC unenforceable_JJ ._.
As_IN noted_VBN above_IN ,_, AstraZeneca_NNP is_VBZ appealing_VBG this_DT ruling_NN in_IN the_DT patent_NN litigation_NN ._.
AstraZeneca_NNP denies_VBZ the_DT allegations_NNS of_IN this_DT anti-trust_JJ complaint_NN and_CC will_MD vigorously_RB defend_VB the_DT lawsuit_NN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC 124_CD Form_NN 20-F_JJ Information_NN 2005_CD NOTES_NNS TO_TO THE_DT FINANCIAL_NNP STATEMENTS_NNS CONTINUED_VBD 25_CD COMMITMENTS_NNS AND_CC CONTINGENT_JJ LIABILITIES_NNS CONTINUED_VBD AstraZeneca_NNP continues_VBZ to_TO maintain_VB that_IN its_PRP$ patents_NNS for_IN Toprol-XL_NNP are_VBP valid_JJ ,_, enforceable_JJ and_CC infringed_VBN by_IN the_DT proposed_VBN generic_JJ products_NNS of_IN KV_NNP ,_, Andrx_NNP and_CC Eon_NNP and_CC that_IN its_PRP$ enforcement_NN of_IN its_PRP$ patents_NNS did_VBD not_RB violate_VB anti-trust_JJ laws_NNS ._.
Zestril_NNP lisinopril_NN In_IN 1996_CD ,_, two_CD of_IN AstraZenecas_NNP predecessor_NN companies_NNS ,_, Zeneca_NNP Limited_NNP and_CC Zeneca_NNP Pharma_NNP Inc._NNP as_IN licensees_NNS ,_, Merck_NNP &_CC Co._NNP ._.
Inc._NNP and_CC Merck_NNP Frosst_NNP Canada_NNP Inc._NNP commenced_VBD a_DT patent_NN infringement_NN action_NN in_IN the_DT Federal_NNP Court_NNP of_IN Canada_NNP against_IN Apotex_NNP Inc._NNP alleging_VBG infringement_NN of_IN Mercks_NNP lisinopril_NN patent_NN ._.
Apotex_NNP has_VBZ sold_VBN and_CC continues_VBZ to_TO sell_VB a_DT generic_JJ version_NN of_IN AstraZenecas_NNP Zestril_NNP and_CC Mercks_NNP Prinivil_NNP tablets_NNS ._.
Apotex_NNP has_VBZ admitted_VBN infringement_NN but_CC has_VBZ raised_VBN positive_JJ defences_NNS to_TO infringement_NN ,_, including_VBG that_IN it_PRP acquired_VBD certain_JJ quantities_NNS of_IN lisinopril_NN prior_RB to_TO issuance_NN of_IN the_DT patent_NN and_CC that_IN certain_JJ quantities_NNS were_VBD licensed_VBN under_IN a_DT compulsory_JJ licence_NN ._.
Apotex_NNP has_VBZ also_RB alleged_VBN invalidity_NN of_IN the_DT patent_NN ._.
The_DT trial_NN started_VBD in_IN January_NNP 2006_CD ._.
AstraZeneca_NNP as_IN licensee_NN has_VBZ a_DT case_NN pending_VBG in_IN the_DT Federal_NNP Court_NNP of_IN Canada_NNP against_IN Cobalt_NNP Pharmaceuticals_NNP Inc._NNP pertaining_VBG to_TO the_DT same_JJ Merck_NNP lisinopril_NN patent_NN ,_, on_IN the_DT basis_NN that_WDT Cobalt_NNP is_VBZ seeking_VBG a_DT notice_NN of_IN compliance_NN marketing_NN approval_NN in_IN Canada_NNP based_VBN on_IN a_DT comparison_NN with_IN AstraZenecas_NNP Zestril_NNP ._.
AstraZeneca_NNP is_VBZ potentially_RB liable_JJ for_IN damages_NNS in_IN the_DT event_NN that_WDT Cobalts_VBZ market_NN entry_NN is_VBZ held_VBN to_TO have_VB been_VBN improperly_RB delayed_VBN ._.
Zestoretic_JJ lisinopril_NN hydrochlorothiazide_NN AstraZeneca_NNP as_IN licensee_NN has_VBZ a_DT case_NN pending_VBG in_IN the_DT Federal_NNP Court_NNP of_IN Canada_NNP against_IN Apotex_NNP Inc._NNP pertaining_VBG to_TO Mercks_NNP lisinopril_NN hydrochlorothiazide_NN combination_NN patent_NN ,_, on_IN the_DT basis_NN that_WDT Apotex_NNP is_VBZ seeking_VBG a_DT notice_NN of_IN compliance_NN marketing_NN approval_NN in_IN Canada_NNP based_VBN on_IN a_DT comparison_NN with_IN AstraZenecas_NNP Zestoretic_NNP ._.
AstraZeneca_NNP is_VBZ potentially_RB liable_JJ for_IN damages_NNS in_IN the_DT event_NN that_WDT Apotexs_VBZ market_NN entry_NN is_VBZ held_VBN to_TO have_VB been_VBN improperly_RB delayed_VBN ._.
Average_JJ wholesale_JJ price_NN class_NN action_NN litigation_NN In_IN January_NNP 2002_CD ,_, AstraZeneca_NNP was_VBD named_VBN as_IN a_DT defendant_NN along_IN with_IN 24_CD other_JJ pharmaceutical_JJ manufacturers_NNS in_IN a_DT class_NN action_NN suit_NN ,_, in_IN Massachusetts_NNP ,_, brought_VBD on_RP behalf_NN of_IN a_DT putative_JJ class_NN of_IN plaintiffs_NNS alleged_VBN to_TO have_VB overpaid_VBN for_IN prescription_NN drugs_NNS as_IN a_DT result_NN of_IN inflated_JJ wholesale_JJ list_NN prices_NNS ._.
The_DT suit_NN seeks_VBZ to_TO recover_VB unspecified_JJ damages_NNS ._.
Following_VBG the_DT Massachusetts_NNP complaint_NN ,_, nearly_RB identical_JJ class_NN action_NN suits_NNS were_VBD filed_VBN against_IN AstraZeneca_NNP and_CC various_JJ other_JJ pharmaceutical_JJ manufacturers_NNS in_IN four_CD other_JJ states_NNS ._.
AstraZeneca_NNP and_CC other_JJ manufacturers_NNS have_VBP since_IN been_VBN sued_VBN in_IN similar_JJ lawsuits_NNS filed_VBN by_IN the_DT state_NN Attorneys_NNP General_NNP of_IN Pennsylvania_NNP ,_, Nevada_NNP ,_, Montana_NNP ,_, Wisconsin_NNP ,_, Illinois_NNP ,_, Alabama_NNP ,_, Kentucky_NNP ,_, Arizona_NNP and_CC Mississippi_NNP ,_, as_RB well_RB as_IN by_IN multiple_JJ individual_JJ counties_NNS in_IN the_DT State_NN of_IN New_NNP York_NNP ._.
The_DT Attorney_NNP General_NNP lawsuits_NNS seek_VBP to_TO recover_VB alleged_JJ overpayments_NNS under_IN Medicaid_NNP and_CC other_JJ state-funded_JJ healthcare_NN programs_NNS ._.
In_IN several_JJ cases_NNS ,_, the_DT states_NNS are_VBP also_RB suing_VBG to_TO recover_VB alleged_JJ overpayments_NNS by_IN state_NN residents_NNS ._.
Many_JJ of_IN these_DT suits_NNS have_VBP been_VBN consolidated_VBN with_IN the_DT Massachusetts_NNP action_NN for_IN pre-trial_JJ purposes_NNS ,_, pursuant_JJ to_TO federal_JJ multi-district_JJ litigation_NN procedures_NNS ._.
In_IN August_NNP 2005_CD ,_, the_DT District_NNP Court_NNP in_IN Boston_NNP issued_VBD a_DT decision_NN on_IN class_NN certification_NN favourable_JJ to_TO the_DT defendants_NNS ._.
The_DT plaintiffs_NNS in_IN the_DT consolidated_JJ class_NN action_NN suit_NN had_VBD sought_VBN to_TO certify_VB three_CD types_NNS of_IN nationwide_JJ classes_NNS of_IN plaintiffs_NNS :_: 1_CD Medicare_NNP Part_NNP B_NNP beneficiaries_NNS who_WP paid_VBD allegedly_RB inflated_JJ co-insurance_NN for_IN certain_JJ drugs_NNS reimbursed_VBN under_IN the_DT Medicare_NNP Part_NNP B_NNP program_NN :_: 2_CD third_JJ party_NN insurers_NNS offering_VBG coverage_NN for_IN the_DT same_JJ drugs_NNS :_: and_CC 3_CD third_JJ party_NN insurers_NNS for_IN certain_JJ self-administered_JJ non-Part_JJ B_NN drugs_NNS ._.
The_DT court_NN denied_VBD the_DT self-administered_JJ drug_NN class_NN entirely_RB ._.
As_IN to_TO the_DT proposed_VBN classes_NNS involving_VBG drugs_NNS ,_, the_DT court_NN certified_VBD a_DT nationwide_JJ class_NN of_IN Part_NNP B_NNP beneficiaries_NNS against_IN AstraZeneca_NNP and_CC three_CD other_JJ manufacturers_NNS ._.
The_DT additional_JJ proposed_VBN classes_NNS involving_VBG drugs_NNS ,_, third_JJ party_NN payers_NNS who_WP reimbursed_VBD for_IN drugs_NNS or_CC who_WP covered_VBD Part_NNP B_NNP co-payments_NNS ,_, have_VBP been_VBN certified_VBN only_RB as_IN Massachusetts_NNP state_NN ,_, as_IN opposed_VBN to_TO nationwide_JJ ,_, classes_NNS ._.
For_IN all_DT classes_NNS ,_, the_DT only_JJ AstraZeneca_NNP drug_NN at_IN issue_NN is_VBZ Zoladex_NNP goserelin_NN acetate_NN implant_VBP ._.
There_EX is_VBZ a_DT possibility_NN that_IN the_DT decision_NN on_IN class_NN certification_NN will_MD be_VB appealed_VBN ._.
Following_VBG a_DT decision_NN on_IN the_DT appeal_NN ,_, the_DT court_NN will_MD set_VB a_DT schedule_NN for_IN summary_NN judgement_NN proceedings_NNS and_CC trial_NN ._.
In_IN the_DT interim_NN ,_, Attorney_NNP General_NNP cases_NNS are_VBP proceeding_VBG independently_RB of_IN the_DT consolidated_JJ action_NN in_IN Pennsylvania_NNP ,_, Alabama_NNP ,_, Mississippi_NNP ,_, Arizona_NNP and_CC Wisconsin_NNP ._.
AstraZeneca_NNP denies_VBZ the_DT allegations_NNS made_VBN in_IN all_DT of_IN the_DT average_JJ wholesale_JJ price_NN lawsuits_NNS and_CC will_MD vigorously_RB defend_VB the_DT actions_NNS ._.
340b_JJ class_NN action_NN litigation_NN In_IN August_NNP 2004_CD ,_, AstraZeneca_NNP was_VBD named_VBN as_IN a_DT defendant_NN along_IN with_IN multiple_JJ other_JJ pharmaceutical_JJ manufacturers_NNS in_IN a_DT class_NN action_NN suit_NN filed_VBN in_IN the_DT Alabama_NNP federal_JJ court_NN on_IN behalf_NN of_IN all_DT share_NN entities_NNS ._.
These_DT are_VBP the_DT hospitals_NNS and_CC clinics_NNS that_WDT treat_VBP a_DT substantial_JJ portion_NN of_IN uninsured_JJ patients_NNS and_CC thus_RB qualify_VB for_IN preferential_JJ pricing_NN under_IN the_DT US_NNP Public_NNP Health_NNP Service_NNP Act_NNP drug_NN discount_NN program_NN the_DT 340b_JJ program_NN ._.
According_VBG to_TO the_DT complaint_NN ,_, the_DT genesis_NN of_IN the_DT suit_NN is_VBZ an_DT audit_NN report_NN by_IN the_DT US_NNP Department_NNP of_IN Health_NNP and_CC Human_NNP Services_NNP Office_NNP of_IN Inspector_NNP General_NNP OIG_NNP in_IN June_NNP 2004_CD ._.
A_DT similar_JJ class_NN action_NN suit_NN was_VBD filed_VBN in_IN August_NNP 2005_CD by_IN the_DT County_NNP of_IN Santa_NNP Clara_NNP in_IN the_DT California_NNP state_NN court_NN ._.
In_IN the_DT second_JJ suit_NN ,_, the_DT County_NNP of_IN Santa_NNP Clara_NNP is_VBZ suing_VBG as_IN a_DT representative_NN of_IN a_DT class_NN of_IN similarly_RB situated_VBN counties_NNS and_CC cities_NNS in_IN California_NNP alleged_VBD to_TO have_VB overpaid_VBN for_IN 340b_JJ drugs_NNS ._.
AstraZeneca_NNP believes_VBZ the_DT allegations_NNS in_IN both_DT of_IN these_DT lawsuits_NNS are_VBP without_IN merit_NN and_CC intends_VBZ to_TO defend_VB them_PRP vigorously_RB ._.
Financial_NNP Statements_NNP 125_CD 25_CD COMMITMENTS_NNS AND_CC CONTINGENT_JJ LIABILITIES_NNS CONTINUED_VBD Additional_JJ government_NN investigations_NNS into_IN drug_NN marketing_NN practices_NNS As_IN is_VBZ true_JJ for_IN most_JJS ,_, if_IN not_RB all_DT ,_, major_JJ prescription_NN pharmaceutical_JJ companies_NNS operating_VBG in_IN the_DT US_NNP ,_, AstraZeneca_NNP is_VBZ currently_RB involved_VBN in_IN multiple_JJ US_NNP federal_JJ and_CC state_NN criminal_JJ and_CC civil_JJ investigations_NNS into_IN drug_NN marketing_NN and_CC pricing_NN practices_NNS ._.
Two_CD of_IN the_DT active_JJ investigations_NNS are_VBP being_VBG handled_VBN by_IN the_DT US_NNP Attorneys_NNP Office_NNP in_IN Boston_NNP ._.
The_DT first_JJ involves_VBZ a_DT request_NN for_IN production_NN of_IN documents_NNS and_CC information_NN relating_VBG to_TO speaker_NN programs_NNS involving_VBG healthcare_NN professionals_NNS at_IN three_CD regional_JJ healthcare_NN entities_NNS in_IN the_DT Boston_NNP area_NN ._.
The_DT second_JJ involves_VBZ a_DT subpoena_NN for_IN documents_NNS and_CC information_NN relating_VBG to_TO marketing_NN and_CC sales_NNS interactions_NNS with_IN a_DT leading_VBG provider_NN of_IN pharmacy_NN services_NNS to_TO long_JJ term_NN care_NN facilities_NNS ._.
In_IN October_NNP 2004_CD ,_, AstraZeneca_NNP received_VBD a_DT subpoena_NN from_IN the_DT US_NNP Attorneys_NNP Office_NNP in_IN Philadelphia_NNP principally_RB seeking_VBG documents_NNS relating_VBG to_TO the_DT formulary_JJ status_NN of_IN AstraZeneca_NNP drugs_NNS at_IN a_DT regional_JJ health_NN maintenance_NN organization_NN and_CC a_DT national_JJ pharmacy_NN benefits_NNS manager_NN ._.
Most_RBS recently_RB ,_, AstraZeneca_NNP ,_, along_IN with_IN 12_CD other_JJ pharmaceutical_JJ manufacturers_NNS ,_, was_VBD served_VBN with_IN a_DT subpoena_NN from_IN the_DT US_NNP Attorneys_NNP Office_NNP in_IN Philadelphia_NNP seeking_VBG documents_NNS in_IN connection_NN with_IN the_DT governments_NNS pending_VBG civil_JJ litigation_NN against_IN Medco_NNP Health_NNP Systems_NNPS ._.
That_DT subpoena_NN seeks_VBZ documents_NNS relating_VBG to_TO contracts_NNS ,_, programs_NNS ,_, grants_NNS or_CC payments_NNS to_TO Medco_NNP ._.
In_IN January_NNP 2006_CD ,_, AstraZeneca_NNP first_RB received_VBD notice_NN of_IN an_DT investigation_NN by_IN the_DT US_NNP Attorneys_NNP Office_NNP in_IN Los_NNP Angeles_NNP into_IN field_NN promotional_JJ activities_NNS in_IN the_DT area_NN served_VBN by_IN AstraZenecas_NNP Los_NNP Angeles_NNP regional_JJ business_NN center_NN ._.
AstraZeneca_NNP has_VBZ been_VBN provided_VBN with_IN little_JJ information_NN concerning_VBG the_DT nature_NN of_IN the_DT investigation_NN ,_, other_JJ than_IN a_DT representation_NN that_IN the_DT government_NN is_VBZ looking_VBG into_IN the_DT preparation_NN and_CC dissemination_NN of_IN patient_JJ education_NN and_CC similar_JJ materials_NNS to_TO physicians_NNS ._.
It_PRP is_VBZ not_RB possible_JJ to_TO predict_VB the_DT outcome_NN of_IN any_DT of_IN these_DT investigations_NNS ,_, which_WDT could_MD include_VB the_DT payment_NN of_IN damages_NNS and_CC the_DT imposition_NN of_IN fines_NNS ,_, penalties_NNS and_CC administrative_JJ remedies_NNS ._.
Drug_NN importation_NN anti-trust_JJ litigation_NN In_IN May_NNP 2004_CD ,_, plaintiffs_NNS in_IN a_DT purported_JJ class_NN action_NN filed_VBD complaints_NNS in_IN the_DT US_NNP District_NNP Court_NNP for_IN Minnesota_NNP and_CC for_IN New_NNP Jersey_NNP ,_, alleging_VBG that_IN AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP and_CC eight_CD other_JJ pharmaceutical_JJ manufacturer_NN defendants_NNS conspired_VBD to_TO prevent_VB American_JJ consumers_NNS from_IN purchasing_VBG prescription_NN drugs_NNS from_IN Canada_NNP ,_, depriving_VBG consumers_NNS of_IN the_DT ability_NN to_TO purchase_VB drugs_NNS at_IN competitive_JJ prices_NNS ._.
The_DT New_NNP Jersey_NNP case_NN was_VBD voluntarily_RB dismissed_VBN in_IN July_NNP 2004_CD ._.
In_IN August_NNP 2005_CD ,_, the_DT Minnesota_NNP District_NNP Court_NNP dismissed_VBD with_IN prejudice_NN the_DT plaintiffs_NNS federal_JJ anti-trust_JJ claims_NNS and_CC declined_VBD to_TO exercise_VB supplemental_JJ jurisdiction_NN in_IN relation_NN to_TO the_DT state_NN statutory_JJ and_CC common_JJ law_NN claims_NNS ,_, which_WDT claims_VBZ were_VBD dismissed_VBN without_IN prejudice_NN ._.
The_DT plaintiffs_NNS have_VBP appealed_VBN the_DT district_NN courts_NNS decision_NN ._.
In_IN August_NNP 2004_CD ,_, Californian_NN retail_JJ pharmacy_NN plaintiffs_NNS filed_VBD an_DT action_NN in_IN the_DT Superior_NNP Court_NNP of_IN California_NNP making_VBG similar_JJ allegations_NNS ._.
In_IN July_NNP 2005_CD ,_, the_DT court_NN overruled_VBD in_IN part_NN and_CC sustained_VBN in_IN part_NN ,_, without_IN leave_NN to_TO amend_VB ,_, the_DT defendants_NNS motion_NN to_TO dismiss_VB the_DT plaintiffs_NNS third_JJ amended_VBN complaint_NN in_IN these_DT proceedings_NNS ._.
The_DT court_NN overruled_VBD the_DT defendants_NNS motion_NN in_IN respect_NN of_IN conspiracy_NN claims_NNS but_CC sustained_VBD the_DT motion_NN in_IN respect_NN of_IN the_DT California_NNP Unfair_NNP Competition_NNP Law_NNP claims_VBZ ._.
Discovery_NNP is_VBZ ongoing_JJ and_CC the_DT trial_NN is_VBZ scheduled_VBN for_IN September_NNP 2006_CD ._.
AstraZeneca_NNP denies_VBZ the_DT material_NN allegations_NNS of_IN both_DT the_DT Minnesota_NNP and_CC California_NNP actions_NNS and_CC is_VBZ vigorously_RB defending_VBG these_DT matters_NNS ._.
StarLink_NNP AstraZeneca_NNP Insurance_NNP Company_NNP Limited_NNP AZIC_NNP has_VBZ commenced_VBN arbitration_NN proceedings_NNS in_IN the_DT UK_NNP against_IN insurers_NNS in_IN respect_NN of_IN amounts_NNS paid_VBN by_IN Garst_NNP Seed_NN Company_NN of_IN the_DT US_NNP in_IN settlement_NN of_IN claims_NNS arising_VBG in_IN the_DT US_NNP from_IN Garsts_NNPS sale_NN of_IN StarLink_NNP ,_, a_DT genetically_RB engineered_VBN corn_NN seed_NN ._.
The_DT English_NNP High_NNP Court_NNP has_VBZ ruled_VBN ,_, on_IN appeal_NN by_IN reinsurers_NNS from_IN a_DT preliminary_JJ finding_NN in_IN AZICs_NNP favor_NN by_IN the_DT arbitration_NN panel_NN ,_, that_IN English_NNP law_NN applies_VBZ to_TO recovery_NN under_IN the_DT reinsurance_NN arrangements_NNS ._.
This_DT is_VBZ contrary_JJ to_TO AZICs_NNP view_NN ,_, which_WDT is_VBZ that_IN recovery_NN should_MD be_VB assessed_VBN under_IN Iowa_NNP law_NN ,_, and_CC AZIC_NNP is_VBZ seeking_VBG leave_NN to_TO appeal_VB this_DT finding_NN to_TO the_DT Court_NNP of_IN Appeal_NNP ._.
AstraZenecas_NNP interest_NN in_IN Garst_NNP was_VBD through_IN AstraZenecas_NNP 50_CD %_NN ownership_NN of_IN Advanta_NNP BV_NNP ,_, the_DT sale_NN of_IN which_WDT to_TO Syngenta_NNP AG_NNP was_VBD announced_VBN in_IN May_NNP 2004_CD and_CC completed_VBN in_IN September_NNP 2004_CD ._.
AZICs_NNS claim_VBP against_IN the_DT insurers_NNS was_VBD not_RB affected_VBN by_IN the_DT disposal_NN of_IN AstraZenecas_NNP interest_NN in_IN Advanta_NNP BV_NNP ._.
Aptium_NNP Oncology_NNP In_IN April_NNP 2004_CD ,_, Comprehensive_NNP Cancer_NNP Centers_NNPS ,_, Inc._NNP ._.
CCC_NNP ,_, a_DT subsidiary_NN of_IN Aptium_NNP Oncology_NNP formerly_RB called_VBD Salick_NNP Health_NNP Care_NNP received_VBD a_DT subpoena_NN from_IN the_DT US_NNP Department_NNP of_IN Justice_NNP seeking_VBG ,_, among_IN other_JJ items_NNS ,_, medical_JJ records_NNS and_CC related_VBN documentation_NN for_IN services_NNS provided_VBN to_TO patients_NNS at_IN the_DT Comprehensive_NNP Cancer_NNP Center_NNP at_IN Desert_NNP Regional_NNP Medical_NNP Center_NNP in_IN Palm_NNP Springs_NNP ,_, California_NNP ._.
The_DT Center_NNP is_VBZ managed_VBN by_IN CCC_NNP ,_, which_WDT is_VBZ co-operating_JJ fully_RB with_IN the_DT document_NN request_NN ._.
Avorelin_NNP In_IN 1999_CD ,_, AstraZeneca_NNP UK_NNP Limited_NNP entered_VBD into_IN a_DT licence_NN agreement_NN with_IN Mediolanum_NNP farmaceutici_NNS SpA_NNP under_IN which_WDT Mediolanum_NNP licensed_VBD to_TO AstraZeneca_NNP certain_JJ rights_NNS in_IN respect_NN of_IN avorelin_NN ,_, a_DT luteinising_VBG hormone-releasing_NN hormone_NN agonist_NN ._.
At_IN the_DT end_NN of_IN 2000_CD ,_, AstraZeneca_NNP terminated_VBD the_DT agreement_NN ._.
Mediolanum_NNP commenced_VBD proceedings_NNS against_IN AstraZeneca_NNP alleging_VBG that_IN AstraZeneca_NNP breached_VBD the_DT terms_NNS of_IN the_DT agreement_NN and_CC claiming_VBG damages_NNS ._.
This_DT matter_NN has_VBZ now_RB been_VBN settled_VBN by_IN the_DT parties_NNS on_IN terms_NNS satisfactory_JJ to_TO AstraZeneca_NNP which_WDT admits_VBZ no_DT liability_NN ._.
